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Post-transcriptional Control of the epithelial-tomesenchymal transition (EMT) in Ras-driven
colorectal cancers
Chaitra Rao, Ph.D.
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Abstract
Colorectal cancer (CRC) originates from epithelial cells lining the colon or rectum
of the gastrointestinal tract. Most cancer deaths result from a tumor spreading to distant
organs; however epithelial cells do not normally migrate from their tissue of origin. To do
so, epithelial cells undergo biochemical changes allowing them to acquire behavior
similar to motile mesenchymal cells termed the epithelial-to-mesenchymal transition
(EMT), which contributes to tumor invasion and metastasis. Our study demonstrated that
CRC cells require a molecular scaffold, Kinase Suppressor of Ras 1 (KSR1), and ERK to
promote the EMT-like phenotype through the preferential translation of Epithelial Stromal
Interaction 1 (EPSTI1). Disruption of KSR1 or EPSTI1 significantly impairs cell migration
and invasion in vitro, and reverses the EMT-like phenotype, in part, by decreasing the
expression of N-cadherin and of the transcriptional repressors of E-cadherin expression,
Zeb1, and Slug, allowing restoration of E-cadherin expression. In CRC cells lacking
KSR1, ectopic EPSTI1 expression restored the E- to N-cadherin switch, migration,
invasion.
Our data further determined that KSR1-dependent mRNAs with predicted binding
sites for Serine/arginine-rich Splicing Factor 9 (SRSF9) were disproportionately depleted
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by KSR1 knockdown. KSR1 disruption inhibits SRSF9 protein stability. Like KSR1,
SRSF9 knockdown inhibits invasive behavior by CRC cells coincident with its ability to
decrease N-cadherin expression in CRC. We further demonstrated SRSF9 interacts with
EPSTI1 mRNA and a specific splice form of EPSTI1 is optimum for the EMT-like
phenotype. Collectively, our data demonstrate that KSR1-dependent induction of the
EMT-like phenotype via selective post-transcriptional regulation of mRNAs reveals its
underappreciated role in remodeling the translational landscape of CRC cells to promote
their migratory and invasive behavior.
Finally, we examined the effect of MAPK pathway inhibition with and without
KSR1 to evaluate the role of KSR1 as co-dependent signaling promoting Ras/MAPK
pathways. Our data show that under anchorage independent conditions CRISPR/Cas9mediated KSR1 knockout markedly enhances the sensitivity of CRC cells to RAF, MEK,
and ERK inhibitors. Furthermore, resistance to the MEK inhibitor, trametinib in CRC cells
is prevented by KSR1 knockout. These data reveal that KSR1 as an essential
component of MEK activity and highlight the value of disrupting KSR1 to suppress drug
resistance.
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1. Chapter 1: Introduction

2

Overview

The premise of precision oncology is to identify and develop effective therapies
to the most viable targets [1, 2]. Cancer cells have complex rewired pathways for growth
and survival that underlie their tumorigenic phenotype. The key to successful therapeutic
targeting is the identification of critical targets whose inhibition should be exclusive to the
tumor or play an inconsequential role, at least acutely, in normal tissue to minimize
toxicity to the patient. Given the ability of tumors to adapt to, or escape, targeted
therapy, multiple targets, and a comprehensive genetic map of the evolutionary
strategies used by a heterogeneous tumor to survive assault are likely essential.
Physiological dependence of cancer cells to continuous activation of genes to initiate
and maintain the tumor phenotype convey “oncogene addiction” [3]. These adaptations
are necessary for the establishment and maintenance of the oncogenic state and
therefore are reasonable drug targets. Efforts to develop cancer therapeutics targeting
oncogenes have yielded many successes, particularly kinase inhibitors including but not
limited to trastuzumab for HER2, imatinib targeting BCR-ABL, gefitinib for EGFR, and
bevacizumab targeting VEGF (reviewed in [4]). However, to maintain their phenotypic
manifestations, most oncogenes rely on genes that do not harbor activating mutations
but are involved in tumor initiation and maintenance. These proteins or regulatory RNAs
encoded by these genes are often downstream, rate-limiting, or supportive of oncogenedriven signal transduction pathways. The addiction of cancer cells to the functions of
‘non-oncogenes’ is termed as “non-oncogene addiction” and this characteristic refers to
the elevated dependence of cancer cells on the cellular functions of otherwise normal
genes and their products [5, 6]. Importantly, these genes and pathways are essential to
support the oncogenic phenotype but are not required to the same degree for normal cell
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viability. From a genetic perspective, these dependencies can provide an ample number
of drug targets that when inhibited will effectively kill the tumor cells. The identification of
normal genes repurposed by oncogenic drivers to support the tumor phenotype must be
inferred from the literature and tested systematically. Their potential to be targeted with a
high therapeutic index is also difficult to predict. The landscape of non-oncogenic
addiction is vast and unexplored; thus, functional screens to identify the components of
non-oncogene addiction pathways would be valuable and reveal new opportunities in
cancer therapeutics.
Mitogen activated protein kinase (MAPK) pathways represent ubiquitous signal
transduction pathways that regulate many important physiological processes including
cell proliferation, differentiation, immune function, and physiological stress responses [7].
These pathways can be aberrantly activated in disease, including cancer. Signaling
through the RAF/MEK/ERK pathway controls all phases of tumor development and is
critical in cancer therapy as the effectors are largely responsible for the ability of tumor
cells to survive or die following therapy. Extensive work has been focused on identifying
oncogene-driven therapies targeting this pathway and elucidating mechanisms of
sensitivity and resistance. Most of these inhibitors show limited efficacy due to either
acquired resistance of the targeted tumor cells or dose-limiting toxicity in clinical trials.
Strategies to methods for reducing the effective dose have the potential to delay or
suppress acquired resistance and expand the utility of a given pathway inhibitor in
cancer therapy.
To ensure signal specificity, MAPK signaling pathway effectors RAF, MEK, and
ERK are held in close proximity via scaffold proteins [8]. The molecular scaffold Kinase
Suppressor of Ras 1 (KSR1) is a potent modulator of the MAPK signaling cascade [912]. As predicted for such an effector of “non-oncogene addiction” signaling, Ksr1-/- mice
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and cells derived from those mice grow and develop normally but are resistant to
tumorigenesis and transformation by oncogenic Ras. Transformation can be rescued by
restoration of KSR1 expression [13-15]. In colorectal cancer (CRC) cells, disruption of
KSR1 decreases tumorigenesis in vivo [16]. Although, KSR1 is present both in nontransformed and transformed cells, KSR1 is essential to oncogenic Ras-driven cancers.
Given that KSR1 is dispensable for normal cells, but indispensable for CRC cells, we
sought to detect and exploit vulnerabilities that might arise in tumor cells as a result of its
disruption or inactivation.

Targeted therapy for metastatic colorectal cancer (CRC)

Colorectal Cancer (CRC) is the third leading causes of cancer-related mortality
and morbidity in men and women [17]. Screening tests for CRC have improved disease
prognosis by identifying early-stage CRC and advances in primary and adjuvant
treatments have improved the overall survival time. The ideal CRC treatment is to
achieve complete removal of the tumor by surgical intervention [18]. Metastasis is a
multistep process by which tumor cells in the primary site undergo a series of events to
disseminate and form secondary tumor at distant site. Almost half of the patients
undergoing primary CRC resection develop metastases during their lifespan [19].
Despite development of treatment regimens, there is no effective therapy for patients
with advanced CRC [19]. Signaling pathways that are active in CRC are strongly
regulated within the tumor. Targeted therapy is an optional approach that addresses
specific properties of the tumor, which has contributed to improvement in the overall
survival of patients with metastatic CRC. Approximately, 80% of all CRCs express or
overexpress epidermal growth factor receptor (EGFR), which is associated with reduced
overall survival and increased risk of metastasis [18]. Activating Ras mutations, present
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in one-third of CRC, with codons 12 and 13 being the most commonly affected, are
known to be both drivers of tumorigenesis and metastases as well as determinants of
response to therapeutic regimens [20]. Given the complexity of signaling networks, not
all existing CRC-related targets can be successfully inhibited, and a current treatment
regimen covers only a handful of recommended CRC-targeted agents from the
guidelines such as the National Comprehensive Cancer Network (NCCN) [21]. For
patients harboring tumors with high EGFR expression and wild-type BRAF and Ras,
treatment with monoclonal antibodies against EGFR, such as cetuximab and
panitumumab, has significant clinical benefit [18, 22]. However, there are limited
therapeutic interventions targeting mutant Ras function [20, 23], with tumors harboring
Ras mutations showing negative benefits and resistance to EGFR therapies. Therefore,
identifying effectors that transmit signals emanating from oncogenic Ras is a valuable
step in detecting and targeting the adaptive pathways that CRC cells use to resist
targeted therapy [22]. A complementary strategy to target tumors with activating Ras
mutation is to identify addicted and codependent signaling pathways essential for tumor
survival with effective therapeutic inhibition of Ras-effector signaling pathways (Figure
1.1).
Aberrant activation of epithelial-to-mesenchymal transition (EMT) yields cancer
cells with enhanced metastatic potential, leading to acquisition of therapeutic resistance,
which increases the challenge of cancer treatment. In CRC, loss of epithelial and gain of
mesenchymal-like phenotype, enables tumor cells to migrate through the extracellular
matrix and enter the lymphatics or blood vessels, thereby initiating the first step of the
metastatic cascade and increased invasiveness [24, 25]. Understanding the critical roles
of these pathways in CRC tumorigenesis may aid in identifying strategies for
combination therapy that overcome resistance. Effective combinations will be needed to
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Figure 1.1 Strategy of targeted therapy in colorectal cancer.
Oncogenic driver mutations in the MAPK signaling pathway occur in >50% of
colorectal cancers (CRC). However, the occurrence of acquired resistance in tumors
is a challenge to treatment. Novel therapeutic approaches that can either delay
resistance or treat resistant cancers are required to enhance patient outcomes. This
observation highlights the need for studying early adaptive resistant tumor cell
populations and the mechanisms governing their shift to acquired resistance. The
schematic depicts a model of tumor outcomes following targeted therapy in CRC,
suggesting a mechanism whereby inhibiting non-oncogene targets in the MAPK
signaling pathway will limit cancer cell survival and enhance the therapeutic efficacy
of oncogene-targeted therapies. This work aims to characterize non-oncogenicKSR1-signaling downstream of Ras and build a rationale for therapeutic targeting of
KSR1 in colon cancer. Figure was created with BioRender.com
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block these signaling pathway at multiple nodes, both to disrupt the feedback
mechanisms that overcome inhibitor action and to disrupt resistance mechanisms that
render cancer cells non-addicted to the signaling [5]. Combining inhibitors may have a
drastic effect on the tumor growth.

The epithelial-to-mesenchymal transition (EMT) in cancers

The epithelial-to-mesenchymal transition is a crucial cell plasticity program invoked
during embryonic development and normal tissue homeostasis, including wound healing.
When executed, epithelial cells lose polarity and cell-cell contacts and acquire a
mesenchymal phenotype which facilitates motility and invasion, due to profound
remodeling of gene expression [26]. During the multistep progression of cancer, EMT is
aberrantly activated in epithelial cells to acquire distinct mesenchymal traits that confer to
them the ability to invade adjacent tissues and disseminate to distant tissues [26, 27]. The
phenomenon of EMT was first recognized by Elizabeth Hay in the primitive streak of
chick embryos and described as epithelial-to-mesenchymal transformation. She
observed a family of relatively sedentary epithelial cells transform to invasive cell types
that can invade extracellular matrix and migrate great distances in the embryo [28].
However, to distinguish this process from neoplastic transformation, which is commonly
used in the cancer research community, the epithelial-to-mesenchymal transformation
was alternatively referred as epithelial-to-mesenchymal transition [26]. Recently EMT
studies are primarily focused on understanding tissue morphogenesis during
development, and cell behavior and invasiveness in cancer progression. The complexity
of mechanisms impacting EMT in cancer highlights a challenge to its investigation and
the need to characterize new mechanisms driving EMT [29, 30].
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During EMT, changes in gene expression and mechanisms of post-transcriptional
regulation mechanisms lead to suppression of the epithelial phenotype and the acquisition of
mesenchymal characteristics. The molecular regulators of EMT are thought to support all
stages of cancer from tumor initiation to establishment of primary lesions, to accumulation of
genetic alterations, escape from immune surveillance and development of resistance to
therapies [31]. EMT can be transient and reversible representing a continuous shift between
epithelial-like and mesenchymal-like phenotypes, therefore it can be executed partially [32,
33]. Partial EMT is probably the most relevant form because the cancer cells are placed in a
dynamic window of phenotypic plasticity rendering cells with increased adaptability and
resistance to therapy. Moreover, partial E/M states are enriched by tumor initiating cells
(TICs) or cancer stem cells (CSCs) that may provide a survival advantage in different
environments, such as primary and secondary tumor sites.
Proteins involved in transcriptional control contribute to one of the best characterized
regulatory networks during EMT, however their expression alone is not sufficient to
indicate the occurrence of EMT [34] (Figure 1.2). E- and N-cadherins belong to the typeI family of classical cadherins along with P-, R- and M-cadherin [35, 36]. E-cadherin is a
transmembrane glycoprotein that plays a role in calcium-dependent cell-cell adhesion
[37]. E-cadherin is the major component of adherent junctions in epithelial cells. Through
homophilic interactions with other cells, E-cadherin creates a bridge connecting the
adjoining cells to ensure maintenance of characteristic cell cohesion and shape [38].
Loss of E-cadherin at the membrane has been associated with carcinoma progression
and EMT [39-42]. Transcriptional activation of EMT is mediated by a core set of EMTactivating transcription factors (EMT-TFs) that have been found to control cell-cell
adhesion and cell migration. The core EMT-TFs include Twist (Twist-related protein 1),
Snail (SNAI1/ SNAI2) and Zeb (zinc-finger E-box-binding homeobox 1/2)
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Figure 1.2 Molecular contributors to the epithelial-to-mesenchymal transition
(EMT) in cancer.
During EMT, epithelial cells undergo biochemical changes that drive behavior
characteristic of mesenchymal cells and contribute to tumor invasion and metastasis.
Induction of EMT leads to the expression of the EMT-inducing transcription factors
(EMT-TFs) Zeb, Snail and Twist, which inhibit the expression of genes associated
with the epithelial state and coincidently activate the expression of genes associated
with the mesenchymal state. EMT occurs through the highly metastatic partial EMT
state encompassing both epithelial and mesenchymal properties necessary for
efficient self-renewal and metastasis. Figure was created with BioRender.com
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which are activated in response to diverse oncogenic signaling pathways [36]. Through
the influence of EMT-TFs over components of cellular adhesions, especially E-cadherin,
loss of epithelial cell polarity, and enhanced cell motility, these transcriptional regulators
are critical for the induction of EMT programs. EMT-TFs are also linked to the induction
and maintenance of stemness [43, 44] and changes in cell metabolism [45-47] that are
concurrent with EMT. EMT-TFs were shown to be overexpressed in cancers cells
lacking characteristics of complete execution of EMT or also in collectively migrating cell
clusters, indicating that they are preferentially active in cells lacking overt EMT
phenotypes and largely based on activation of partial/hybrid EMT phenotype [26, 27, 48,
49]. Although the influence of EMT-TFs over E-cadherin through the disruption of cellular
adhesions and loss of epithelial cell polarity is critical for EMT induction, it is unlikely to
be the sole determining factor for invasion and metastasis. Inappropriate induction of
non-epithelial cadherins such as N-cadherin by epithelial cells are known to play a
fundamental role during initiation of metastasis [36, 50-55]. N-cadherin disassembles
adherens junction complexes, disrupting the intercellular cohesion and reorienting the
migration of cells, away from the direction of cell-cell contact [50, 56]. Upregulation of Ncadherin expression has been shown to promote motility and invasion [50-52, 57]. Thus,
central to the process of EMT is the coordinated loss of E-cadherin expression and the
upregulation of N-cadherin gene expression, termed as cadherin switching [35, 36, 5860]. Therefore, cadherin switching from E- to N-cadherin in tumors not only triggers a
signaling program that enhances invasive and survival capacities of cancer cells, but
also promotes cooperation between cancer cells and the surrounding environment that
is a critical event in metastatic progression [61].
Previous studies have demonstrated crosstalk between oncogenically activated
Ras and EMT, either through Ras or its downstream effector signaling pathways and the
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activation of EMT-TFs [62-68]. Enhanced expression of ERK2 and not ERK1 has been
linked with Ras-dependent regulation of EMT [62]. The binding of FRA-1 with
phosphorylated ERK2 at the docking site(s) for ERK (DEF domain on ERK) promoted
EMT-TF, Zeb protein expression or vimentin expression, and increased cell motility and
invasion in cancer cells [62-64]. Also, oncogenic Ras itself activates EMT and the EMTTF, Slug [66, 67]. These studies show that the expression of Ras or MEK/ERK resulted
in increased expression of mesenchymal markers, decreased expression of E-cadherin,
and can be sufficient for EMT in colon and breast epithelial cells [62, 67, 68]. The KSR1effectors; Myc, PGC1α, and ERRα, have also been implicated to induce characteristics
of EMT in various cancers. Myc was shown to drive Zeb1-dependent EMT through the
suppression of E-cadherin expression in breast and lung epithelial cells [69, 70]. PGC1α
and ERRα overexpression upregulated the expression of N-cadherin and promoted the
migratory capacity of breast cancer cells [71]. Silencing of Erbin, a tumor suppresser
known to disrupt KSR1-RAF1 interaction, promoted cell migration and invasion of colon
cancer cells grown in 3-D culture [72]. Taken together, these data support the idea that
Ras-dependent KSR1/ERK signaling plays a crucial role in the regulation of EMT and its
biological consequence during metastatic progression of cancer. Mediators of EMT have
been recently shown to be preferentially activated by cap-dependent translation initiation
mechanisms associated with increased aggressiveness and metastases of cancer cells
[73-75]. These studies suggest the potential drawback of analyzing gene expression to
identify mediators of epithelial plasticity, which cannot interrogate the role played by
post-transcriptional regulation of mRNA and its translation in tumorigenesis. Besides
transcriptional reprogramming during EMT, post-transcriptional mechanisms such as
alternative pre-mRNA splicing and post-transcriptional modifications and translational
regulation or protein internalization provide an additional layer of gene regulation
contributing to EMT [73, 74, 76].

12

Translation control contributing to EMT

Oncogenic signals have long been recognized to modulate the translational
machinery to selectively synthesize proteins with the available limited resources while
maintaining tumor growth and survival. Eukaryotic translation initiation factor eIF4E is
limiting in normal cells but is overexpressed in cancer. Remarkably, eIF4F deregulation
elicits only small increases in global protein synthesis, while enabling substantial,
disproportionate, and selective translation of mRNAs that play a key role in promoting
tumor development and progression [77]. eIF4E is key regulator of translation initiation
that binds to the 5′ cap structure (m7GpppN). eIF4E interacts with eIF4G and eIF4A to
form eIF4F, the translation initiation complex that recruits the 40 S ribosomal subunit to
mRNA [78, 79]. A major mechanism regulating eIF4E activity is through its interaction
with the transition inhibitory family of 4E binding proteins (4EBP) discovered as
interactors and inhibitors of translation initiation factor eIF4E, characterized as
repressors of overall RNA translation. 4EBP proteins compete with eIF4G for the binding
to eIF4E, thereby preventing the assembly of eIF4F [80]. Notably, 4EBPs act as a nexus
for regulation of cap-dependent translation by multiple signaling pathways and their
inactivation represents a major mechanism by which oncogenic signaling promotes
translation of mRNAs that are key for tumor maintenance and progression.
Hypophosphorylated 4EBPs bind to eIF4E and inhibit cap-dependent translation.
4EBP1 phosphorylation has been reported on multiple sites: Thr 37, Thr 46, Ser 65, Thr
70, Ser 83, Ser 101, and Ser 112. Phosphorylation of Thr 37 and Thr 46 serves as a
priming event, which is followed by Thr 70 phosphorylation and finally Ser 65
phosphorylation. Hypophosphorylated 4EBP1 allows its interaction with eIF4E, and
prevents the binding of eIF4G, thereby inhibiting complex assembly and preventing
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translation [80]. Phosphorylation of 4EBP1 by mTORC1 results in the dissociation of
4EBP1 from eIF4E, which promotes translation by allowing the formation of eIF4F
complex [78, 79]. Inactivation of 4EBPs appears to be critical for colon tumor
development by ERK and AKT-mTOR signaling [78]. The selective dependence of tumor
cells on eIF4E and 4EBP activity reflects the fact that inhibition of cap-dependent
translation affects the translation of a subset of mRNAs encoding proteins in cell cycle
progression and cell survival [79].
Several mechanisms of translation fuel invasive behavior in cancer cells
(Reviewed in [81-83]). Key features of mRNAs may contribute to their preferential
translation orchestrated by oncogenic signaling. RNA binding proteins (RBPs) interact
with sequence-specific regulatory elements in the untranslated regions of genes that
have been functionally associated with altered loading on to the polysomes in response
to pro-tumorigenic signaling. A number of factors have been implicated in dictating the
reliance of these mRNAs on RBPs, including a highly structured 5′ UTR and/or the
presence of specific cis elements in the 5′ UTR such as a 5′ TOP (5′ terminal
oligopyrimidine tract), PRTE (pyrimidine-rich translation element) or a CERT (cytosineenriched regulator of translation). Two notable motifs, guanine/uridine-rich element
(GRE) and cytoplasmic polyadenylation element (CPE) found in the 3′ UTR, modulate
translation of genes important for EMT, including SNAIL and Twist1 respectively [84, 85].
mRNAs encoding SNAIL and MMP3 are translated in an eIF4E-dependent manner
downstream of the TGFβ-MNK axis [86]. The phosphorylated eIF4α-ATF4 axis can
induce EMT, dedifferentiation and breast cancer invasion [82]. Post-transcriptional
regulation of EMT-related RNAs by RBPs is another mechanism involved in the
regulation of EMT in cancer cells [87, 88]. Since EMT is believed to be the central
mechanism in cancer cell dissemination and metastasis, identifying molecular
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mechanisms that can interfere with alternative splicing or mRNA translation involved in
these processes could potentially be explored as a therapeutic strategy.

Kinase suppressor of Ras as a potent modulator of Ras signaling

Kinase suppressor of Ras (KSR) was identified from genetic screens in
Drosophila melanogaster and Caenorhabditis elegans as a modulator Ras-RAF-ERKmediated signaling [12]. In both systems KSR contributes positively to ERK
phosphorylation and its subsequent activation. KSR function is more critical for the effect
of mutant activated Ras than the effect of wild-type Ras. In mammalian cells, KSR1 and
KSR2 act as molecular scaffolds, binding to RAF, MEK, and ERK, and facilitating their
phosphorylation and activation in a dose-dependent fashion [8, 9, 11, 12]. KSR functions
as a gate to control flux through the MAPK pathway (Figure 1.3). KSR1 is constitutively
bound to MEK1/2 and Impedes Mitogenic Signal Propagation (IMP) [89-92]. KSR1 is
phosphorylated on S297 and S392 by C-TAK1 in quiescent cells and is maintained in an
inactive state by cytosolic 14-3-3 proteins bound to these phosphorylation sites [9, 12,
93]. Activation of Ras catalyzes IMP autophosphorylation and proteasomal destruction,
which stimulates KSR1 dephosphorylation by PP2A and its translocation to the plasma
membrane [94]. These events facilitate the activation of MEK by RAF. MEK1/2 is
dissociates from KSR1 and allows ERK1/2 phosphorylation. KSR1/2 includes an FXFP
motif that is known as DEF (docking site for ERK) which is a critical component for
mediating interaction of KSR with ERK [95]. The above observations suggest that KSR1
provides spatial control of signaling through the Ras/RAF/MEK/ERK kinase cascade.
KSR1 is required for oncogenic Ras-induced transformation in mouse embryonic
fibroblasts (MEFs) [11, 93], is overexpressed in human CRC cell lines, and is
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Figure 1.3 Signaling dynamics of Kinase Suppressor of Ras 1.
KSR1 drives increased translation of the oncogene Myc in an ERK-dependent
manner. KSR1/2 interact with subunits of AMPK and promote tumor growth. KSR1
signaling also promotes the expression of PGC1β and ERRα in an ERK-independent
manner, PGC1β and ERRα promote tumor formation in part via changes in oxidative
phosphorylation, glycolysis, and lipid biosynthesis. Figure was created with
BioRender.com
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dispensable for normal cell survival [16, 96-98]. While KSR2 is highly expressed in brain,
it is expressed in low levels in other tissues. There are differences in the phenotype of
ksr1-/- and ksr2-/- mice, indicating that KSR1 and KSR2 have unique and distinct
physiological roles, but it is highly likely that biochemically there is significant overlap in
their function. ksr1-/- knockout mice are fertile and phenotypically and developmentally
normal but are resistant to Ras-driven tumor formation [11, 15]. These observations
suggest that KSR1, or KSR1-mediated effectors, may serve as highly selective
therapeutic targets. Further, disrupting KSR1 in CRC cells using RNAi in CRC cells
potently decreases tumor cell transformation in vitro and tumor growth in vivo. Inhibiting
KSR1 mRNA expression using a continuous infusion of phosphorothioate antisense
oligonucleotides caused a drastic regression of established Ras-driven pancreatic and
non-small cell lung cancer xenografts, PANC-1 and A549, respectively and suppressed
metastasis suggesting a potential strategy to target Ras-driven pancreatic cells [99].
In striking contrast to KSR1, ksr2-/- mice have reduced fertility and show severe
early onset of obesity and insulin resistance, suggesting that KSR2 has a role in energy
homeostasis [100]. KSR2 mRNA is highly expressed in the brain and pituitary, and
selective disruption of KSR2 in the brain is sufficient to cause the mice to become
spontaneously obese and glucose intolerant [100, 101]. Whole-exome sequencing of
KSR2 in 1,770 individuals identified several mutations in KSR2 that were associated with
an increased risk of severe early-onset obesity. HEK293 cells transfected with mutant
forms of KSR2 demonstrated impaired glucose oxidation and palmitate-stimulated fatty
acid oxidation compared to the HEK293 cells transfected wild-type KSR2 [102]. These
observations showed that KSR2 depletion is characterized by hyperphagia, decreased
metabolic rate, severe insulin resistance and leptin-sensitive food consumption. A novel
relationship between KSR1/KSR2 and AMP-activated protein kinase (AMPK) subunits
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has been demonstrated to promote tumorigenesis. KSR1/2 interactions with AMPK
disrupt normal glucose metabolism and fatty acid oxidation and alter the regulation of
energy balance indicating that these scaffolds may affect energy balance in normal
tissue and tumor cells [100, 103]. AMPK is an important regulator of cellular energy and
acts a fuel sensor. Under conditions of stress and nutrient deprivation, the intracellular
AMP/ATP ratio is increased, and the AMP promotes activation of AMPK that activates
catabolic processes and inhibits anabolic pathways. The decreased rates of glycolysis
and fatty acid oxidation upon KSR2 disruption are restored with the expression of
constitutively active AMPKα2. KSR proteins play a role as a metabolic regulator of
glucose metabolism and adipogenesis [104, 105]. Depletion of endogenous KSR1
results in defective adipogenesis in vitro which is rescued by low levels of a KSR1
transgene. A gene-expression signature, Functional Signature Ontology (FUSION), was
developed to identify functional analogues of KSR1 [96-98, 106, 107]. In order to identify
proteins with functional similarity to KSR1, a gene-expression signature that represents
the loss of KSR1 was used to screen an arrayed siRNA library containing multiple
siRNAs per gene targeting a total of 14,335 proteins. FUSION identified a subunit of
AMPK, AMPKγ1 as preferentially required for colon cancer survival and progression
[108]. KSR1 and AMPK are both necessary for oncogenic Ras-induced expression of
transcriptional regulators PGC1β and ERRα which are overexpressed in metastatic CRC
cells [16].
Studies indicate that KSR1 and ERK drive cap-dependent and cap-independent
translation of the oncogene Myc in CRC cells. KSR1 regulates the cap-dependent and
cap-independent translation of Myc through the repression of the translation initiation
inhibitor, 4EBP1, and the inhibitor of the eIF4A helicase, programmed cell death 4 (PDCD4).
In addition, KSR1-dependent ERK activation promotes the increased translation of Myc,
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that acts as a transcription factor to enhance the expression of PGC1β and its
transcriptional partner ERRα [98]. ERRα functions downstream of PGC1β and increases
the expression of genes whose products function in the TCA cycle, oxidative
phosphorylation, and lipid metabolism [109]. KSR1 and KSR2 serve as signaling nodes
that respond to oncogenic signaling while ensuring the availability of enough nutrients
and energy supply. Perhaps, an inhibitor targeting KSR1 that is efficacious and has
minimum side effects is necessary. An inadequate understanding of the differences
between the physiological roles of KSR1 and KSR2 is a limitation to current research.
Thus, further studies are required to identify the mechanism of how KSR regulates cell
function and thereby identify opportunities for targeting the mitogenic and metabolic
arms necessary for cancer growth and survival. Identification of effectors downstream of
KSR1 critical for the cancer phenotype will reveal novel mechanisms that may be
targeted to improve therapeutic response and inhibit tumor initiation and metastasis.

Goal of the study

Increasing evidence points to the importance of alterations in translational control in
tumorigenesis. Tumor cells have an increased dependence on the translation machinery for
their sustained proliferation and survival that is not seen in normal cells. However,
exploitation of this potential will require understanding of the mechanisms underlying
selective upregulation of translation of mRNA relevant in cancer cells. Therefore, the
premise of the proposed study is that the characterization of pathways dependent on nononcogenic a.k.a. KSR1-signaling downstream of Ras will identify novel targets and
strategies for CRC therapy that will have minimal side effects in patients. The overall goal of
this study was to expand mechanistic understanding of post-transcriptional dysregulation
critical for tumor initiation, maintenance, and mediating therapy resistance in CRC cells.
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This project aimed to understand how tumor-specific mechanisms including pre-mRNA
splicing and mRNA translation enable the expression of selective mRNAs essential for
tumor growth, invasion, and survival. These studies will reveal a novel role for alternative
splicing and post-transcriptional control of RNAs involved in tumor initiation and
metastasis. Combination therapy approaches will be needed to achieve a prolonged
anti-tumor response and potentially reduce therapy resistance.
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2. Chapter 2: Materials and Methods
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Cell culture

The colorectal cancer cell lines HCT116, HCT15 and SW480 (Table 5) were
acquired from American Type Culture Collection (ATCC). The cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose with 10% fetal
bovine serum (FBS) and grown at 37ºC with ambient O2 and 5% CO2. Cells were tested
negative for mycoplasma. The non-transformed immortalized human colon epithelial cell
line (HCEC) was a gift from J. Shay (University of Texas [UT] Southwestern) and the
cells were grown and maintained as described previously [16, 110]. HCECs were grown
in a hypoxia chamber with 2% O2 and 5% CO2 at 37°C in 4 parts DMEM to 1 part
medium 199 (Sigma-Aldrich #M4530) with 2% cosmic calf serum (GE Healthcare,
#SH30087.03), 25 ng/mL EGF (R&D, Minneapolis, MN #236-EG), 1 µg/mL
hydrocortisone (Sigma-Aldrich, #H0888), 10 µg/mL insulin (Sigma-Aldrich, #I550), 2
µg/mL transferrin (Sigma-Aldrich, #T1428), 5 nM sodium selenite (Sigma-Aldrich

#S5261), and 50 µg/mL gentamicin sulfate (Gibco #15750-060) as described
previously [16]. Normal and quadruple mutant KAPS (KRASG12D/APC KO/ P53
KO

/SMAD4KO) tumor colon organoids were obtained from the Living Organoid Biobank

developed by Dr. Hans Clevers and were cultured as described previously [111, 112].
The normal organoids were cultured in medium containing advanced DMEM/F12
(Invitrogen #12634) with 50% WNT conditioned media (produced using stably
transfected L cells), 20% R-spondin1, 10% Noggin, 1X B27 (Invitrogen #17504-044), 10
mM nicotinamide (Sigma-Aldrich #N0636), 1.25 mM N-acetylcysteine (Sigma-Aldrich
#A9165-5G), 50 ng/mL EGF (Invitrogen #PMG8043), 5 µM TGF- type I receptor
inhibitor A83-01 (Tocris #2939), 10 nM Prostaglandin E2 (Tocris #2296), 3 µM p38
inhibitor SB202190 (Sigma-Aldrich #S7067), and 100 µg/mL Primocin (Invivogen #ant-
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pm-1). The quadruple mutant KAPS organoids were grown in media lacking WNT
conditioned medium, R-spondin 1, noggin and EGF and containing 10 µM nutlin-3
(Sigma #675576-98-4).

RNA interference

Approximately 500,000 cells were transfected using a final concentration of 20
nM ON-TARGETplus siRNAs targeting EPSTI1/SRSF9/RASD1/ERK/non-targeting
control (Table 6) from GE Healthcare Dharmacon using 20 µL of Lipofectamine
RNAiMAX (ThermoFisher #13778-150) and 500 µL OptiMEM (ThermoFisher
#31985070). Cells were incubated for 72 hours before further analysis. Because of the
low transfection efficiency observed in HCT15 cells, SW480 cells were used to analyze
the effects of SRSF9 knockdown in Chapter 5.

Generation of KSR1 shRNA knockdown and KSR1 CRISPR/Cas9
knockout cell lines

Lentiviral pLKO.1-puro constructs encoding shRNAs targeting KSR1, and nontargeting control (Table 6) were transfected into HEK-293T cells using the trans-lentiviral
packaging system (ThermoFisher Scientific). The viral supernatant was collected and
filtered through a 0.45 µM membrane filter. 8 µg/mL of Polybrene was added to 1.5 ml of
the supernatant. The supernatant was mixed with 0.5 ml of media containing 500,000
HCT116 or HCT15 cells, plated in 6-well dishes, and incubated for 96 hours. The
population of cells with depleted KSR1 was selected with 10 µg/mL puromycin. KSR1
knockdown was confirmed via Western blotting.
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pCAG-SpCas9-GFP-U6-gRNA was a gift from Jizhong Zou (Addgene plasmid
#79144), KSR1 sgRNA and non-targeting control sgRNA (Table 6) were cloned into the
pCas9 vector. Both the non-targeting control and sgKSR1 were transfected into
HCT116, HCT15 and SW480 cells using PEI transfection as described previously [113].
GFP-positive cells were sorted 48-hours post transfection, and colonies were picked by
placing sterile glass rings around individual colonies.
pMSCV-IRES-GFP, pMSCV-IRES-KSR1-GFP and, pMSCV-IRES-KSR1AAAPGFP were previously generated in the lab [93] (Table 6) . EPSTI1 transcript variant 1,
accession number BC023660, protein ID AAH23660.1 was purchased from Horizon
Discovery (#MHS6278202832484). To generate Flag EPSTI1 IRES GFP, full length 410
amino acid cDNA was PCR amplified (amino acids 2-410) with an N-terminal Flag tag
and with flanking restriction sites EcoRI and SalI. This was inserted into the EcoRI and
XhoI sites of expression vector pMSCV IRES GFP.
To generate EPST1 isoform X1 (399 amino acids) accession number
XM_005266596.1, protein ID XP_005266653, amino acids 220-230 were removed (Δ
exon 8) from transcript variant 1 using Quikchange site directed mutagenesis, and Flag
EPSTI1 tv1 pMSCV IRES GFP as the template resulting EPSTI1 tv X1 pMSCV IRES
GFP.
To generate EPSTI1 transcript variant 2 (Δ exons 8,12, and 13) accession
number NM_033255.3, protein ID NP_150280, Flag EPSTI1 tv X1 pMSCV IRES GFP
was used as a template to PCR amplify amino acids 2-307. The N-terminal Flag was
included as well, and the EcoRI-SalI fragment was inserted into the EcoRI and XhoI
sites of expression vector pMSCV IRES GFP resulting in Flag EPSTI1 tv2 pMSCV IRES
GFP.
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To generate EPSTI1 transcript variant 3 (Δ exons 12 and 13), accession number
NM_001330543.2, protein ID NP_001317472.1, Flag EPSTI1 tv1 pMSCV IRES GFP
was used as a template to PCR amplify amino acid acids 2-318 including the N-terminal
Flag, and the product was inserted into the EcoRI and XhoI sites of pMSCV IRES GFP
as an EcoRI-SalI fragment, resulting in Flag EPSTI tv3 pMSCV IRES GFP. All the above
constructs were Sanger sequence verified (primer sequences listed in Table 7).
All the above constructs were transfected into Phoenix GP (HEK293T GP) cells
using the trans-lentiviral packaging system (ThermoFisher Scientific). The viral
supernatant was collected and filtered through a 0.45 µM membrane filter. 8 µg/mL of
Polybrene was added to the 1.5 ml of the supernatant. The supernatant was mixed with
0.5 ml of medium containing 1,00,000 cells of HCEC cells or 500,000 KSR1-CRISPR
HCT116, HCT15, or SW480 cells, plated in 6-well dishes, and incubated for 96 hours.
Cells expressing KSR1, EPSTI1 or N-cadherin transgenes were selected for GFP
fluorescence using fluorescence-activated cell sorting (FACS). KSR1, EPSTI1, or Ncadherin expression was confirmed by Western Blotting.

Cell lysis and Western blot analysis

Whole cell lysate was extracted in radioimmunoprecipitation assay (RIPA) buffer
containing 50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na deoxycholate, 0.1% Na
dodecylsulfate, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, and 1X protease and
phosphatase inhibitor cocktail (Halt, ThermoFisher Scientific #78440). Cytoplasmic and
nuclear fractionation was performed using NE-PERTM Nuclear and Cytoplasmic
Extraction Reagents (ThermoFisher Scientific #PI78835). Estimation of protein
concentration was done using the BCA protein assay (Promega #PI-23222, PI-23224).
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Samples were diluted using 1X sample buffer (4X stock, LI-COR #928-40004) with 100
mM dithiothreitol (DTT) (10X stock, 1 M, Sigma #D9779-5G). The proteins were
separated using 8-12% SDS-PAGE and transferred to nitrocellulose membrane. The
membrane was blocked with Odyssey TBS blocking buffer (LICOR-Biosciences #92750003) for 45 minutes at room temperature, and then incubated with primary antibodies
(Table 8) at least overnight at 4ºC. IRDye 800CW and 680RD secondary antibodies (LICOR Biosciences # 926-32211, # 926-68072) were diluted 1:10,000 in 0.1% TBS-Tween
and imaged on the Odyssey Classic Scanner (LI-COR Biosciences).

Polysome profiling

Cells were treated with 100 µg/mL cycloheximide (Sigma #C4859) on ice in PBS
for 10 minutes. The cells were lysed with 10 mM HEPES pH 7.4, 100 mM KCl, 5 mM
MgCl2, 100 µg/mL cycloheximide, 2 mM DTT, 1% Triton-X100, and 2.5 µl RNaseOUT
(ThermoFisher Scientific #10777019). The lysates were cleared by centrifugation for 10
minutes at 13,200 rpm at 4ºC. Approximately 200 µL of the total RNA solution was
collected in a new RNAse-free microcentrifuge tube and the remaining supernatant was
loaded onto a 15-45% sucrose gradient. The samples were spun at 37,500 rpm for 2
hours at 4ºC in an SW55Ti Beckman ultracentrifuge and separated on a gradient
fractionation system to resolve the polysomes. Polysome profiles were identified at 260
nM using an absorbance detector. Gradient fractions were collected dropwise at 0.75
mL/min. For RNAseq, the total RNA and RNA pooled from the polysome fraction
(fractions 6-9) of three sets of independently isolated cells was isolated using RNAzol
(Molecular Research Centre #RN 190) according to the manufacture’s protocol. RNA
purity was evaluated by the UNMC DNA Sequencing Core using a BioAnalyzer.
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RNA sequencing and analysis

RNA sequencing (RNAseq) was conducted by the UNMC DNA Sequencing
Core. For RNAseq, RNA was purified from three replicates of total and polysome-bound
RNA from HCT116 and HCT15 control and KSR1 knockdown cells (twenty-four samples
total) as previously described. Stranded RNA sequencing libraries were prepared as per
the manufacturer’s protocol using the TrueSeq mRNA protocol kit (Illumina) and 500 ng
of the total RNA was used for each of the samples. Purified libraries were pooled at a
0.9 pM concentration and sequenced on an Illumina NextSeq550 instrument, using a 75
SR High-output flow cell, to obtain approximately 45 million single-end reads per sample.
NGS short reads from RNAseq experiments were downloaded from the HiSeq2500
server in FASTQ format. FastQC
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to perform quality
control checks on the fastq files that contained the raw short reads from sequencing.
The reads were then mapped to the Homo sapiens (human) reference genome
assembly GRCh38 (hg38) using STAR v2.7 alignment. The --quantMode GeneCounts
option in STAR 2.7 [114] was used to obtain the HTSeq counts per gene. Gencode v32
Gene Transfer Format (GTF) was used for the transcript/gene annotations. The output
files were combined into a matrix using R. The gene counts were further used as input
for downstream analysis using Anota2seq. The high-throughput sequencing data have
been deposited in the Gene Expression Omnibus (GEO) database,
www.ncbi.nlm.nih.gov/geo (accession no. GSE164492).
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Translational Efficiency (TE) analysis

The altered levels of total mRNA can impact the changes in the pool of
polysome-bound mRNA, leading to a spurious calculation of translational efficiency (TE).
Anota2seq [115] allows the quantification of actual changes in TE. TE was calculated
from three replicates of control or KSR1 knockdown HCT116 and HCT15 cells, using the
R Bioconductor anota2Seq package for the HTSeq counts by first removing genes that
did not contain expression values in more than 10% of the samples out of the twentyfour samples in total. 16,023 genes remained after this step. Trimmed Mean of the Mvalues (TMM) normalization was further performed prior to log2 counts per million
computations (CPM) using the voom function of the limma package using the
anota2seqDataSetFromMatrix function (with parameters datatype = “RNAseq”,
normalize = TRUE, transformation = “TMM-log2”). TE was calculated using the 2 X 2
factorial design model for the two cell lines (HCT116 and HCT15). Genes were
considered significantly regulated at Adjusted p-value <.05 when passing filtering criteria
(parameters for anota2seqSelSigGenes function) using Random variance Model
[useRVM = TRUE], [selDeltaPT >log2(1.2)], [minSlopeTranslation >−1],
[maxSlopeTranslation <2], [selDeltaTP >log2(1.2)], [minSlopeBuffering >−2] and
[maxSlopeBuffering <1], [selDeltaP >log2(1)], [selDetaT >log2(1)]. The scatterplots were
obtained using the anota2seqPlotFC function. The heatmaps were generated using the
TE values for the two cell lines using the R Bioconductor ComplexHeatmap package.

Splicing analysis

rMATS analysis was performed using rMATS turbo v4.1.0 starting from the
aligned.out.bam files obtained by mapping the reads to Homo sapiens (human) genome
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assembly GRCh38 (hg38) using STAR v2.7 alignment. Gencode v22 was used for the
transcript/gene annotations.
txt files were used to pass grouping of inputs (case and control) for each
condition in each cell line (HCT15/HCT116) to rMATS respectively using the parameters
"single" for single-end data [ -t single], read length of 76 bp [ --readLength 76 bp] and
allowing reads with lengths that differ from –readLength to be processed [--variableread-length]. The detection of novel splice sites (unannotated splice sites) was enabled
[--novelSS].
The final output files [AS_Event]. MATS.JC.txt and [AS_Event].MATS.JCEC.txt
were combined for further analysis. For visualization of differentially spliced exons,
sashimi plots were generated using rmats2sashimiplot.
rMATS Command
rmats.py --b1 /path/to/case.txt --b2 /path/to/control.txt --gtf /path/to/the.gtf -t
single --readLength 76 --variable-read-length --nthread 15 --tstat 15 --novelSS --od
/path/to/output --tmp /path/to/tmp_output

PRADA

To predict the RNA binding proteins (RBPs) modulated upon KSR1 knockdown,
a computational framework called Prioritization of Regulatory Pathways based on
Analysis of RNA Dynamics Alterations (PRADA) was applied as previously described
[116]. PRADA is a customized variation on lasso regression (least absolute shrinkage
and selection operator) that predicts RBPs whose differential expression explains
changes in the expression of their targets that is observed in the data. Briefly, genes with
RefSeq ID starting with NM (Curated mRNA) were retained for the analysis. Following
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the input of the log2 fold change (TE) values and p-values identified in the Anota2seq
analysis from HCT116 and HCT15 cells, a RBP target matrix was created by scanning
the RBP motif across the fasta sequence of the mRNA targets of interest. The resulting
binary matrix was created where the rows are transcripts, and the columns are RBPs,
and the presence of a putative binding site for RBP on the transcript is set to '1' or ‘0’
otherwise. The penalties were defined as 1/|log2TE|. RBPs whose expression is
informative for predicting the expression of their putative regulon were identified using
glmnet R package that fits generalized linear via penalized maximum likelihood. The
regularization path is computed for the lasso at a grid of values (on the log scale) for the
regularization parameter lambda. The RBPs with the largest assigned coefficients
(absolute value) were prioritized and plotted.

TCGA and CPTAC data analysis

The RNA expression values for EPSTI1 and SRSF9 mRNA expression were
obtained from TCGA data by the UALCAN portal [117] and plotted using GraphPad
Prism. The protein expression in individual stages of colon cancer for EPSTI1 and
SRSF9 was obtained from CPTAC. Z-values represent SD from the median across
samples for the given cancer type. Log2 Spectral count ratio values from CPTAC were
first normalized with each sample profile, then normalized across samples. The data
table plotted was using GraphPad Prism.

Anchorage-independent growth (poly-HEMA) assay

Poly-(HEMA) stock solution (10 mg/mL) was prepared by suspending poly(HEMA) (Sigma #3932-25G) in 95% ethanol at 37ºC until fully dissolved (overnight).
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Ninety-six-well optical bottom plates (Thermo Scientific Nunc #165305) were coated in
200 µL of poly-(HEMA) solution that was allowed to evaporate. Cells were plated in
complete growth medium on the poly-(HEMA) coated plates at a concentration of 10,000
cells/100 µL. Cell viability was measured at the indicated time points by the addition of
CellTiter-Glo 2.0 reagent (Promega #G9242) and luminescence was measured
(POLARstar Optima plate reader) according to the manufacturer’s protocol.

Anchorage-independent growth (soft agar) assay

6,000 cells were seeded in 1.6% NuSieve Agarose (Lonza #50081) to assess
anchorage-independent growth according to the protocol of Fisher et al. [16]. Colonies
greater than 100 µm in diameter from 6 replicates per sample were counted, and
representative photomicrographs were taken after 10-14 days of incubation at 37°C and
5% CO2.

Cell growth assay (AlamarBlue)

10,000 HCT116 cells/well were transfected on white or clear 96-well plates.
Transfections were done as described above but at a ratio of 1:25 for all of the reagents.
72-hours post-transfection, AlamarBlue reagent (ThermoFisher Scientific) was added to
each well at a 1:10 dilution. Plates were incubated at 37°C, 5% CO2, for 1-3 hours.
Fluorescence was measured using the POLARstar OPTIMA machine. Results were
background subtracted (well with medium + AlamarBlue® without any cells) and
normalized with the control being set to 1.
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RT-qPCR

Cells were harvested using 1 mL TRIzol (ThermoFisher Scientific #15596026)
and RNA extraction was performed using RNeasy spin columns (Qiagen #74104). RNA
was eluted with nuclease-free water. The RNA was quantified using a NanoDrop 2000
(Thermo Scientific) and Reverse Transcription (RT) was performed with 2 µg RNA per
40 µl reaction mixture using iScript Reverse Transcription Supermix (Bio-Rad #1708891). RT-qPCR was performed using primers (Table 7), and all targets were amplified
using SsoAdvanced Universal SYBR green Supermix (Bio-Rad #1725271) with 40
cycles on a QuantStudioTM 3 (ThermoFisher Scientific). The analysis was performed
using 2-ΔΔCT method [118]. For polysome gradients, the RNA levels were quantified from
the cDNA using the standard curve method, summed across all fractions (3-8) and
presented as a percentage of the total fractions.

Cell migration (scratch-test) assay

An in vitro scratch test was performed with the IncuCyte Zoom according to the
manufacturer’s instructions. Approximately 35,000 cells were seeded onto a 96-well
ImageLock plates (Essen BioScience #4379) and grown to 90-95% confluency. The
scratches were created using WoundMaker (Essen BioScience #4563) in all the wells,
after which the cells were washed with 1x PBS, and full medium was replaced with
medium without serum. Images of the cells were obtained every 20 minutes for a total
duration of 72 hours using IncuCyte Kinetic Live Cell Imaging System (Essen
BioScience) and analyzed using the IncuCyte Zoom software (Essen BioScience).
IncuCyte Software was used to calculate the relative wound density metric to quantify
cell migration over time. The metric is designed to be zero at t=0 and 100% when cell
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density inside the wound is the same as the cell density outside the initial wound, thus,
allowing for experimentally quantification of the effects of cell migration separately from
changes that occurs as result of cell proliferation.

Cell invasion (Transwell) assay

Transwell inserts (24-well Millicell cell culture, #MCEP24H48) were coated with
50 µL of Matrigel® (Corning, # 356234) and the Matrigel was allowed to solidify for 15-30
minutes. Approximately 20,000 control or knockout cells, or cells after 48 hours of siRNA
transfection were plated in serum-free media in the upper chamber of each transwell
insert. Cells were allowed to invade toward 10% serum-containing medium in the lower
chamber for 24 hours, after which cells and gel in the upper chamber were gently
removed with a sterile cotton applicator and the cells on the lower side of the insert were
fixed with 3.7% formaldehyde for two minutes, permeabilized with 100% methanol for 20
minutes and stained with Giemsa for 15 minutes. The numbers of cells were determined
using an inverted microscope at 20x magnification.

Immunofluorescence assay

Cells were plated on glass coverslips and allowed to grow to 70-80% confluence
for 48 hours in growth medium. Cells were fixed in 1% formaldehyde diluted in PBS for
15 minutes. The cells were rinsed three times with PBS for 5 minutes and coverslips
were blocked for 1 hour with 1X PBS/5% goat serum/0.3% Triton™ X-100 and then
incubated with E-cadherin antibody (#4A2) overnight. Cells were washed three times for
5 min with PBS and incubated in anti-mouse IgG Alexa Fluor® 555 Conjugate (Cell
signaling #4409) at a dilution of 1:500 for 1 hour. Coverslips were rinsed three times for
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5 min in PBS and briefly rinsed in distilled water prior to mounting in Prolong® Gold
Antifade Reagent with DAPI (Cell signaling #8961). All Images were acquired using a
Zeiss LSM-780 confocal microscope and processed using ZEISS ZEN 3.2 (blue edition)
software.

Cell growth assay

Cells were transfected with siRNA targeting EPSTI1 or a non-targeting control as
previously described. The next day, control, KSR1-CRISPR, KSR1-CRISPR HCT116
and SW480 cells expressing KSR1 or EPSTI1, siControl and siEPSTI1 HCT116 and
SW480 cells were counted and approximately 1x104 cells were plated in all wells of a 12well plate for each condition. The next day, four of the wells from each 12-well plate
were harvested and stained with 0.4% trypan blue (Sigma, # T6146-5G) and then
counted and recorded using a Countess II automated cell counter (ThermoFisher,
#A27977). This procedure was repeated for indicated days and the cells from day seven
were harvested and Western blot analysis was performed to ensure the expression of
the target protein was maintained. Cell counts were then graphed in GraphPad.

Ribonucleoprotein immunoprecipitation

Ribonucleoprotein immunoprecipitation (RIP) was performed as previously
described [119]. Briefly, cells were lysed in 20 mM Tris-HCl pH 7.5 containing 100 mM
KCl, 5 mM MgCl2, 0.5% NP-40, and the Halt Protease and Phosphatase Inhibitor
Cocktail (ThermoFisher #78442) and RNase Inhibitors (ThermoFisher, # EO0381).
Immunoprecipitations were performed with precoated anti-SRSF9 or rabbit normal IgGprotein A Sepharose beads (GE Healthcare, catalog number: 17-1279-02) for 2 hours at
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4 °C. The immunoprecipitated protein–RNA complexes were washed three times with 50
mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM MgCl2, 0.05% NP-40. Total RNAs were
purified from the washed beads using Trizol (Qiagen) and subjected to RT–qPCR
analysis using EPSTI1, HPRT1, or GAPDH primers (Table 7).

Dose-response curves

To simulate anchorage-independent conditions, Black-sided, clear bottom, 96well plates (ThermoFisher, Nunc # 165305) were coated with polyHEMA by evaporating
200 µL of the 10 mg/mL stock polyHEMA solution in each well. Cells were seeded at
10,000 cells per well in 100 μL complete medium (2D-adherant studies) or on polyHEMA coated plate (3D-adherant studies) and allowed to attach for 24 hours prior to
drug treatment. Cells were treated with DMSO or respective drugs for 72 hours prior to
assessment of cell viability using CellTiter-Glo 2.0. EC50 values were calculated using
Prism Software (GraphPad, La Jolla, CA) by plotting the log of the drug concentration
against the percent of maximum viability. EC50 values were generated using an
algorithm for fitting non-linear curves, Log (inhibitor) vs normalized response - with
variable slopes (Y=100/(1+10^((LogIC50-X) *HillSlope))).

Multi-well resistance assay

300 cells in 100 µL of complete medium were seeded in 96-well clear bottom
plates (96 wells/cell line) and allowed to attach for 24 hours prior to drug treatment. Cells
were treated with 300 nM (2X concentration of EC85) trametinib, with 100 µl of the 2XDrug was added to each well. The medium was replaced weekly by pouring the old
medium onto an autoclaved tray and adding 200 µL of fresh medium with 1X drug to
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each well. Wells were scored every 3-4 days, and each well was scored resistant if it
was >50% confluent. Percent growth inhibition was plotted as a Kaplan-Meier curve.

Aldeflour assay
The ALDEFLUOR™ reagent kit (STEMCELL technologies, #01700) was used to
identify tumor initiating cells expressing high levels of the enzyme aldehyde
dehydrogenase (ALDH). Following siRNA transfection, the cells were lysed and
resuspended in assay buffer. 5 µL/ml of Aldeflour reagent was added to approximately
1X106 cells and 0.5 ml of the mixture was transferred into a second tube containing 5 µL
of diethylaminobenzaldehyde (DEAB) reagent. The samples were incubated for 45
minutes at 37 ºC and the tubes were centrifuged for 5 minutes at 250 x g. Pellets were
resuspended in 0.5 mL of assay buffer. The presence of ALDH or fluorescence was
measured using a fluorescence-activated cell sorting (FACS). Gating was set using
DEAB stain to control for background fluorescence.

Reagents

The ERK inhibitor SCH772984 (S7101), MEK inhibitors PD325901 (S1036) and
trametinib (GSK1120212, S2673), and RAF inhibitor LY3009120 (S7842) were
purchased from SelleckChem, Z-Leu-Leu-Leu-al (MG132, S2619) was purchased from
ThermoFisher and mTOR inhibitor AZD8055 (HY_10422) was purchased from
MedChem Express.
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3. Chapter 3: Polysome profiling identifies
key genes contributing to colon cancer cell
survival.

Portions of the material covered in this chapter are the subject of a manuscript published in eLife
by Rao et al [120].
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Introduction

Molecular scaffolds affect the intensity and duration of signaling pathways by
coordinating a discrete set of effectors at defined subcellular locations to regulate
multiple cell fates [91, 121]. Kinase Suppressor of Ras 1 (KSR1) serves as a scaffold for
RAF, MEK, and ERK enabling the efficient transmission of signals within the mitogen
activated protein kinase (MAPK) cascade [11, 122]. Although KSR1 is dispensable for
normal development, it is necessary for oncogenic Ras-induced tumorigenesis including
colorectal cancer cell tumor formation [11, 16, 92, 96, 97, 122], suggesting that KSR1
may modulate aberrant signals that redirect the function of effectors typically involved in
normal cellular homeostasis. Activating Ras mutations are present in over 40% of
colorectal cancers (CRC) and associated with advanced disease and decreased overall
survival [123, 124]. Activated Ras, a critical driver of both tumor growth and survival, is
an attractive therapeutic target, yet targeting the majority of oncogenic alleles of Ras is
still a work in progress. RAF/MEK/ERK signaling can phenocopy Ras signaling essential
for CRC growth and survival [125, 126]. Therefore, understanding the effectors that
transmit signals emanating from oncogenic Ras is a valuable step in detecting and
targeting the pathways critical to tumor cell function and their adaptation to therapy.
Oncogene-driven signaling pathways promote mRNA translation that enables
expression of a subset of mRNAs to promote growth, invasion, and metastasis [77-79,
127]. Tumor cells have an increased dependence on cap-dependent translation, unlike
their normal counterparts [77, 128]. Eukaryotic Translation Initiation Factor 4E (eIF4E) is
a rate-limiting factor for oncogenic transformation, with reductions of as little as 40%
being sufficient to block tumorigenesis [77]. eIF4E function is regulated by association
with 4E binding proteins (4EBPs). ERK signaling regulates global and selective mRNA
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translation through RSK1/2-dependent modification of cap-dependent translation [98,
129]. Phosphorylation of cap binding protein 4EBP1 releases eIF4E to promote
translation and the abundance of eIF4E is a rate-limiting factor for oncogenic Ras- and
Myc-driven transformation [77]. We have previously reported that, disruption of KSR1
leads to dephosphorylation and activation of 4EBP1, indicating that the function of KSR1
as an ERK scaffold is key to the aberrant regulation of mRNA translation [98]. This
tumor-specific, KSR1-dependent regulation of mRNA translation of a subset of genes
was predicted to selectively promote survival of CRC cells but not normal colon epithelia
[98, 130]. However, the identity of all the mRNAs globally affected by KSR1-mediated
translation was unknown.
Efforts to globally monitor gene expression have historically focused on
measuring the messenger RNA (mRNA) levels using RNA sequencing (RNAseq).
However, mRNA levels are an imperfect proxy for protein synthesis because mRNA
translation is subject to extensive regulation [128]. Polysome profiling [131], in which
mRNAs are recovered from translating ribosomes for subsequent RNA sequencing
analysis, can provide a meaningful estimate of protein production. Therefore, to identify
the translational landscape modulated by KSR1 signaling, we hypothesized that a
genome-wide polysome profiling screen will identify targets translationally regulated by
KSR1.
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Results

KSR1 or ERK depletion suppresses Myc expression in CRC cell lines and
preclinical colon organoids.
Deregulated and increased expression of Myc is required for colorectal
tumorigenesis. Inhibiting mRNA translation of Myc has emerged as a therapeutic
strategy to target Myc-dependent tumor growth [132-134]. Phosphorylation and inhibition
of 4EBP1 and increased expression of Myc are catalyzed by ERK signaling in the Rasmutant CRC cell line, HCT116 cells [135]. We tested whether the sensitivity of 4E-BP1
and Myc to ERK signaling is also maintained in human colon organoids. We obtained
engineered human colon organoids harboring either a KRas mutation or KRasG12D/
APCKO/P53KO/SMAD4KO (KAPS, quadruple mutant) from the Living Organoid Biobank
established by Dr. Hans Clevers [111]. To evaluate if ERK signaling promotes Myc
translation, we treated KRas mutant and KAPS organoids with either DMSO or 1 µM
ERK inhibitor SCH772984 for 48 hours and assessed Myc, 4EBP1, and PDCD4
expression via immunoblot. ERK inhibition decreased Myc expression in HCT116, KRas
mutant, and KAPS organoids along with decreased phosphorylated 4EBP1 expression
and increased expression of PDCD4 (Figure. 3.1A). We showed previously that KSR1
maximizes ERK activation in the setting of oncogenic Ras [93], which is required for
increased Myc translation supporting CRC cell growth [98]. However, it is not known if
the decrease in Myc translation following ERK inhibition is dependent on KSR1-signaling
in colon cancer cell lines. We generated KSR1 CRISPR KO cells in HCT116 and HCT15
cell lines and we observed a decrease in phosphorylated 4EBP1 and a subsequent
decrease in Myc expression. The levels of phosphorylated 4EBP1 and Myc were
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restored to the levels in control upon expressing a KSR1 transgene in the cells lacking
KSR1. KSR1 contains an FSFP motif that is a DEF docking motif for activated ERK. A
mutated form of KSR1 (FSFP/AAAP) lacks KSR:ERK interaction [92, 93, 95], which is
required for Ras-induced increased proliferation. Expressing the KSR1 construct lacking
the ability to bind ERK in the KSR1 KO HCT116 and HCT15 cells failed to retore Myc
levels observed with the addition of intact KSR1 (Figure. 3.1B). These data indicate that
KSR1-dependent and ERK-mediated signaling is critical for induction of Myc expression.
The observation that KSR1-dependent mechanisms affect Myc expression suggests the
possibility that KSR1-dependent signaling may broadly impact the translational
landscape in CRC cells to support their survival.

Myc and TIMELESS mRNA are translationally regulated by ERK.
A Functional Signature Ontology (FUSION) screen identified TIMELESS as
functionally similar to KSR1 [135]. TIMELESS mRNA and protein expression was
significantly upregulated in a panel of CRC cell lines compared to non-transformed
human colon epithelial cells. Further, activated ERK was shown to promote TIMELESS
expression. Interestingly, the total mRNA of TIMELESS was unchanged following
inhibition of ERK. When polysome-bound mRNA from HCT116 cells was evaluated, the
translation efficiency of TIMELESS was significantly decreased following the addition of
ERK inhibitor [135]. Total Myc protein was reduced upon ERK inhibition, but Myc and
TIMELESS transcript levels were not altered significantly (Figure 3.2A). We performed
polysome profiling in HCT116 cells, either treated with DMSO or ERK inhibitor
SCH772984 and isolated mRNA from low molecular weight (MW) monosome
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Figure 3.1 ERK inhibition or KSR1 depletion suppresses Myc expression.
(A) Western blot analysis of p-RSK, RSK, Myc, PDCD4, p-4EBP1, and 4EBP1 in
(left) HCT116 cells, (middle) human intestinal organoids with KRasG12D mutation or
(right) in human intestinal organoids with KRasG12D, APCKO, P53KO, SMAD4KO (KAPS)
treated with DMSO or 1 µM SCH772984 (ERKi). (B) Western blot analysis of KSR1,
Myc, p-4EBP1 and total 4EBP1 in control and KSR1 KO HCT116 and HCT15 cells
with and without a wild-type (+KSR1) or mutant KSR1 that cannot bind ERK (+ KSR1
AAAP) transgene. The Western blots of the HCT116 cells are representative of two
independent experiments while Western blots of the organoids in Figure 3.1A and
HCT15s in Figure 3.1B were performed once. Figure 3.1A was completed in
collaboration with Drs. Kurt Fisher and Adrian Black.
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(fractions #3-5) and high MW polysome (fractions #6-8) fractions (Figure 3.2B). RTqPCR demonstrated that Myc and TIMELESS mRNA shifted from high-MW fractions to
the low-MW fractions upon ERK inhibition (Figure 3.2C-D, 2F). The distribution of
mRNA for HPRT1 within the same profile was not altered by SCH772984 treatment
(Figure 3.2E). These data indicate that ERK signaling is a critical regulator of
TIMELESS and Myc mRNA translation in HCT116 cells.

KSR1 knockdown suppresses CRC cell viability.
To understand the role of KSR1 in enhancing mRNA translation and survival and
viability of CRC cells, K-Ras mutant CRC cells, HCT116 and HCT15, were engineered
to stably express short hairpin RNA (shRNA) constructs targeting KSR1 or a nontargeting control (MissionⓇ non-target shRNA control 1, MC1) (Figure 3.3A). Depletion
of KSR1 suppressed phosphorylated ERK and had a modest effect on Myc expression.
Cell viability of control and KSR1 knockdown HCT116 and HCT15 cells was measured
by CellTiter-Glo® Luminescent Cell Viability Assay. Although the knockdown of KSR1
did not affect the activity of 4EBP1 or PDCD4, the viability under anchorage-independent
conditions was suppressed in HCT116 and HCT15 cells (Figure 3.3B).
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Figure 3.2 ERK inhibition suppresses Myc or TIMELESS mRNA translation.
(A) RT-qPCR analysis of TIMELESS and Myc mRNA from total RNA in HCT116 cells
treated with either DMSO or ERK1/2 selective inhibitor, 1 µM SCH772984 for 48
hours. (B) Polysome profiles from HCT116 cells treated DMSO or 1 µM of
SCH772984. RT-qPCR analysis of (C) Myc, (D) TIMELESS and (E) HPRT1 mRNA
from fractions 3-5 (low MW) and 6-8 (high MW) are plotted for the DMSO-treated and
ERK inhibitor treated HCT116 cells with values corresponding to the percentage of
total mRNA across these fractions (n=3) and (F) as a bar graph measuring the area
under the curve (AUC) generated using GraphPad prism.
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Genome-wide polysome profiling reveals translational regulation of key genes
required in EMT and self-renewal.
To determine which mRNAs are preferentially translated in response to KSR1dependent signaling, total RNA and polysome-associated RNAs were isolated on linear
sucrose gradients following ultracentrifugation of extracts of CRC cells with or without
KSR1 knockdown (Figure 3.4). We isolated and quantified both total mRNA and
efficiently translated mRNAs (associated with ≥ 3 ribosomes) using RNA sequencing.
Three biological replicates were included in each group. RNA-seq libraries were
prepared using TrueSeqV2 (Illumina) and multiplexed and sequenced on a NextSeq550
system to obtain an average of 45 million single end reads per sample. RNA-seq reads
were aligned to the human genome assembly GRCh37 (hg38) STAR v2.7 alignment and
HTSeq counts per gene were obtained.
We used Anota2seq [115] to calculate translation efficiency (TE) by comparing
the differences in efficiently translated mRNAs to the total transcript of each mRNA.
Anota2seq is an extension of the previous method anota [136] that quantifies TE by
measuring the changes in polysome-associated RNA that are independent of the
variations in cytosolic mRNA levels. Using this method, we observed that a significant
number of mRNAs ([selDeltaTP ≥ log (1.2)] and selDeltaPT ≥ log (1.2)] and p-value
<.05) showed either reduced TE (red dots) or upregulated TE (orange dots) upon KSR1
disruption in both HCT116 and HCT15 cells (Figure 3.5A, Table 3). A total of 40
mRNAs had upregulated TE in both the cell lines while 58 mRNAs had decreased TE
with KSR1 knockdown (Figure 3.5B). The top 40 upregulated and downregulated
protein-coding genes were plotted in a Heatmap comparing the TE in the control and
KSR1 knockdown HCT116 and HCT15 cells (Figure 3.5C).
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Figure 3.3 KSR1 knockdown affects the viability of CRC cells.
(A) Western blot analysis of KSR1, phosphorylated ERK1/2, Myc, PDCD4,
phosphorylated and total 4EBP1 in the control and KSR1 knockdown HCT116 and
HCT15 cells. (B) Viability of HCT116 and HCT15 cells measured using CellTiterGloⓇ following control or KSR1 knockdown that were plated on polyHEMA-coated
plates to simulate anchorage-independent conditions. Cell viability was measured
immediately after plating, Days: 0, 1 and 3 (N=6). Data are presented as relative
luminescence ±SD (****, P<.0001).
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Figure 3.4 Polysome profiling analysis in non-targeting control and KSR1
knockdown HCT116 and HCT15 cells.
Three independent replicates of the polysome profiles from control (shMC1) and
KSR1 knockdown (shKSR1) HCT116 and HCT15 cells. Sucrose gradient fractions 35 denote the low molecular weight complexes (monosomes) and the fractions 6-8 are
the high molecular weight complexes (polysomes).
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Figure 3.5 Anota2seq analysis identifies mRNAs translationally regulated in
KSR1 knockdown CRC cells.
(A) Scatter plot of polysome-associated mRNA to total mRNA log2 fold-changes
upon KSR1 knockdown in HCT116 (top) and HCT15 (bottom) with RNA-seq. The
statistically significant genes in the absence of KSR1 are classified into four groups
with a fold change (|log2FC| > 1.2) and p-value <.05. The number of mRNAs with a
change in TE (orange and red) are indicated (n=3 for each cell line). TE, translational
efficiency (B) Differential gene expression analysis comparing genes whose TE is
changed upon KSR1- knockdown in HCT116 and HCT15 (C) Heatmap of TE
changes for the top 40 RNAs control and KSR1 knockdown (KSR1 RNAi) HCT116
and HCT15 cells (n=3 for each condition). Figure 3.5A was completed with the help
from Siddesh Southekal.
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FUSION and Anato2seq analysis identify RASD1 critical for CRC cell growth.
Under stringent conditions, Anato2seq analysis identified 58 mRNAs whose TE
was reduced upon depletion of KSR1 in both HCT116 and HCT15 cells.
Dexamethasone-induced RAS-1 (RASD1) identified by Anato2seq analysis was also
predicted previously by our genome-scale RNAi screen (FUSION) as critical for CRC cell
survival but not normal cell survival [97, 135]. RASD1 is a small GTPase belonging to
Ras superfamily [137]. Like other members of Ras family, RASD1 consists of highly
conserved GTP-binding and hydrolysis motifs, an effector loop mediating protein-protein
interactions and CAAX box serving as a site for isoprenylation. An extended C-terminal
cationic domain distinguishes RASD1 from other Ras-like proteins. RASD1 serves as a
signaling transducer of multiple signaling pathways including MAPK signaling [138],
calcium ion channels [139], and growth hormone secretion [140]. We confirmed in the
KSR1 knockdown HCT116 and HCT15 cells, that RASD1 protein expression was
decreased (Figure 3.6A). The oncogenic function of RASD1 is debatable. While studies
showed elevated levels of RASD1 in prostate cells [141] and osteosarcoma cell lines
[142], and overexpression of RASD1 enhanced the proliferation of osteosarcoma cells,
overexpression of RASD1 resulted in inhibition of growth in breast cancer and lung
adenocarcinoma cell lines [143]. To understand if RASD1 enhances the viability of CRC
cells, we knocked down RASD1 in HCT116 using two siRNA oligonucleotides and
blotted for PARP expression. RASD1 depletion caused an increase in cleaved PARP
expression (Figure 3.6B). Disruption of RASD1 in HCT116 using RNAi, resulted in a
modest reduction of metabolic capacity measured by AlamarBlue (Figure 3.6C);
however, this result does not measure the transformed properties of the cells. Analyzing
the cells under anchorage-independent conditions may prove that RASD1 depletion is
detrimental to viability of CRC cells as we have found with other FUSION hits.
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Figure 3.6 RASD1 knockdown affects HCT116 cell viability.
(A) Western blot analysis of RASD1 expression in control (shMC1) and KSR1
knockdown (shKSR1) HCT116 and HCT15 cells. (B) Western blot of RASD1 and
PARP in control and RASD1 knockdown HCT116 cells. RASD1 knockdown was
achieved using two siRNA oligonucleotides. (C) AlamarBlue® reagent was added to
HCT116 cells with and without RASD1 knockdown to determine cell viability.
AlamarBlue fluorescence was measured at 0 hour and 3 hours for the same
samples. **, P<.05; ***, P<.005. These data are representative of two independent
experiments.
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Gene Set Enrichment Analysis (GSEA) identifies key KSR1-dependent signaling
pathways.
To better understand how KSR1 impacts the translation of distinct classes of
mRNAs, we performed Gene Set Enrichment Analysis (GSEA) to identify functional
classes of genes whose translation was altered by KSR1 knockdown in HCT116 and
HCT15 cells (98 mRNAs identified from Anota2Seq analysis). This analysis revealed a
diverse group of functional ontologies including classes of genes known to be
downstream of JAK-STAT, inflammatory response and epithelial-to-mesenchymal
transition signaling pathways (Table 1). These data indicate that KSR1 plays an
unexpected role in the maintenance and expansion of effectors within these pathways.
Tumor initiating cells (TICs) are a subpopulation of tumor cells defined by their
ability to self-renew and regenerate the entire heterogeneous tumor population [144,
145]. TICs undergo EMT to drive their dissemination [26]. TICs mediate tumor
recurrence and metastasis, which are key contributors to patient mortality [146]. GSEA
of significantly enriched genes in HCT116 and HCT15 cells identified 11 mRNAs in the
gene set entitled “Hallmark EMT signature”, “Jechlinger EMT Up”, and Gotzmann EMT
up” [147], that had significantly decreased translation upon KSR1 disruption (Table 2).
Several mRNAs translationally regulated by KSR1 in both HCT116 and HCT15 cells
were found to be implicated in tumor initiation (Figure 3.7A). RT-qPCR analysis of the
total and polysome-bound RNAs isolated from control and KSR1 knockdown HCT116
cells validated that the TE of stem-cell related mRNAs was decreased upon KSR1
disruption (Figure 3.7B). These data suggest that KSR1 signaling plays a previously
unappreciated role in driving translation of mRNAs involved in self-renewal or the
interconversion of cells between epithelial and mesenchymal fates.
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Table 1 Gene Set Enrichment Analysis (GSEA) identifies key KSR1-dependent
signaling pathways.
Molecular Signature Databases
Upregulated

NES FDR q-val

IL6 JAK STAT3 SIGNALING
APOPTOSIS
ADIPOGENESIS
P53 PATHWAY
BILE ACID METABOLISM
PEROXISOME
GLYCOLYSIS
ALLOGRAFT REJECTION
IL2 STAT5 SIGNALING
OXIDATIVE PHOSPHORYLATION
INTERFERON GAMMA RESPONSE
ESTROGEN RESPONSE LATE
Downregulated

1.62
1.62
1.54
1.36
1.35
1.33
1.33
1.31
1.30
1.30
1.30
1.22

0.04
0.04
0.06
0.12
0.13
0.13
0.17
0.15
0.14
0.17
0.16
0.21

UV RESPONSE DN
INFLAMMATORY RESPONSE
E2F TARGETS
MYOGENESIS
EPITHELIAL MESENCHYMAL TRANSITION

-1.53
-1.40
-0.72
-0.70
-0.61

0.05
0.14
0.78
0.85
0.94

NES- normalized enrichment score (enrichment score for the gene set after it has been
normalized across analyzed gene sets.), FDR q-val- False Discovery Rate

Table 2 KSR1 translationally regulates mRNAs involved in the EMT phenotype.
Gene Name
TNFRSF12A
VIM
CAPG
CA2
TGFB3
EGR2
NR4A1
FBLN5
ECM1
CHRNB1
NR2F1

Log2FC: Log2 Fold change

Log2FC
HCT116
-0.30
-0.37
-0.17
-0.43
-0.11
-0.76
-0.06
-0.38
HCT15
-0.02
-0.28
-0.39

p-value
0.0282
0.0331
0.0290
0.0392
0.0284
0.0153
0.0418
0.0339
0.0343
0.0397
0.0287
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SW480 cells.

Figure 3.7 KSR1 knockdown decreases the translational efficiency of CSCrelated transcripts.
(A) Heatmap of log2TE changes for the mRNAs implicated in EMT and CSC-function
in control vs. KSR1 knockdown (shKSR1). TE, Translational Efficiency. (B) RT-qPCR
of the indicated mRNAs from total and polysomal RNA in control (control RNAi) and
KSR1 knockdown (KSR1 RNAi) HCT116 cells. (n = 3; ns, non-significant, *, p<.05,
****, p<.0001).
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DLL1 regulates ALDH activity in CRC cells
The Notch ligand DLL1 is strongly associated with polysomes in a KSR1dependent manner (Figure 3.7B). DLL1 is implicated in the maintenance of normal stem
cells in the colonic crypt [148, 149]. DLL1 promotes tumor growth and metastasis, and
DLL1 expressing breast cancer cells have characteristics of tumor-initiating cancer cells
[150]. Therefore, we tested the effect of DLL1 knockdown on Aldehyde dehydrogenase
(ALDH) activity in HCT116 and SW480 cells. Aldehyde dehydrogenases are a group of
redox enzymes highly expressed in stem cells from normal tissue and in TICs [151].
Although stem cell markers CD44+ and CD133+ staining profiles overlap in normal
colonic crypts, they differ markedly from the ALDH1+ profile in normal colon, and only
marginally enrich human colon TICs in comparison to isolation of TICs by ALDH1+ alone
[152]. ALDH activity was measured using Aldeflour assay, DLL1 knockdown markedly
reduced the TIC-containing ALDHhigh population in HCT116 and SW480 CRC cells by
8.3- and 4.2-fold, respectively (Figure 3.8). These data indicate that KSR1-regulation of
translational efficiency affects the formation of CRC TICs in vitro and provide a proof-ofconcept that translation of KSR1-regulated transcripts controls tumor initiating capacity
in CRC cells. Further studies need to be performed by systematically knocking out each
candidate and testing the effect of their loss on clonogenicity and tumor initiation in vitro
and in vivo.

Discussion

Previous studies have shown that KSR1-dependent regulation of mRNA
translation supports survival of transformed colon epithelial cells but not normal colon
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Figure 3.8 DLL1 knockdown suppresses ALDH activity in CRC cell lines.
(Top) Aldeflour staining for ALDH activity in control and DLL1 knockdown HCT116
and SW480 cells. Gating was performed based on DEAB negative control (left),
siControl (middle), siRNA targeting DLL1 (right) in HCT116 and SW480 cells.
(Bottom) Western blot analysis of DLL1 expression in siControl and siDLL1 HCT116
and SW480 CRC cells. Figure 3.8 was completed in collaboration with Dianna
Huisman.
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epithelia [98]. ERK inhibition, similar to disruption of its scaffold, KSR1, regulates Myc
expression by inhibiting its translation in HCT116 cells [135]. We validated the effects of
ERK inhibition on Myc TE. RNA isolation and qPCR analysis of polysome-bound mRNAs
revealed an inhibitory effect of ERK inhibitor on Myc translation in HCT116 cells. Tumor
organoids derived from patients are increasingly being used to broaden our basic
understanding of cancer biology and serve as a critical pre-clinical cancer model [112,
153]. In this study, we also observed the sensitivity of 4EBP1 and Myc to ERK inhibition
in human colon organoids harboring an activating K-RasG12D mutation or KRasG12D/
APCKO/P53KO/SMAD4KO (KAPS), which confirms that the biological mechanism is
preserved in both cell lines and pre-clinical organoid models.
Using KSR1 as a reference standard in a FUSION screen [16, 97, 106], we
previously identified genetic vulnerabilities in CRC cells predicted to support CRC cell
viability. FUSION screen data identified multiple components of the circadian rhythm
pathway as being functionally similar to KSR1 and TIMELESS was among the top
candidates. Activated ERK promoted TIMELESS expression. Interestingly, the total
mRNA of TIMELESS was unchanged following inhibition of ERK. Subsequent analysis
using polysome profiling demonstrated a profound ability of ERK inhibition to shift
TIMELESS mRNA from polysomes to monosomes in HCT116 cells. These data suggest
that ERK activity in CRC cells preferentially promotes TIMELESS translation.
Tumor-specific mRNA translation enables expression of selective mRNAs
essential for tumor initiation, growth, and invasion. The regulation of the essential
components of mRNA translation suggests that KSR1-dependent modifications alter the
translational landscape of CRC cells, and characterizing effectors repurposed by KSR1dependent signaling will reveal specific mechanism(s) critical to cancer cell survival.
However, the identity of other mRNAs preferentially loaded onto ribosomes by KSR1

56
signaling was unknown. This study aimed to detect mRNAs translationally deregulated
by KSR1 depletion. Using a combination of gene targeting followed by genome-wide
polysome profiling screen, we identified key mRNAs implicated in epithelial-tomesenchymal function and tumor initiation that was affected by KSR1 knockdown. Only
mRNAs that were disproportionately regulated in both HCT116 and HCT15 cell lines
were considered candidate hits. This approach enhances the likelihood that our
polysome profiling screen will reveal translationally regulated mRNAs functionally
relevant in CRC cells bearing oncogenic Ras mutations.
Comparison of candidate genes identified in FUSION and anota2seq predicted
RASD1 as a critical regulator of CRC cell survival. RASD1 plays a pivotal role in the
entrainment of the mammalian circadian clock [154], the circadian rhythm is manipulated
by the cancer cells to enhance proliferation. RASD1 is known to regulate the genes
involved in circadian rhythm. However, it is not known if RASD1 regulates the genes
involved in circadian rhythm in CRC cells, or if depletion of RASD1 affects the
expression of CLOCK, BMAL1/ARNTL, CRY, or other genes known to be involved in the
regulation of circadian rhythm. Though the effect of RASD1 suppression on HCT116
viability is modest in 2D culture, further studies are warranted to study the effect of
RASD1 in CRC.
The ability of KSR1 to regulate the association of EMT and CSC-related mRNAs
with polysomes suggested that KSR1 is important for CRC cell EMT and stemness.
These data support the idea that in CRC cells, KSR1 is necessary for the translation of
mRNAs that contribute to invasion and tumor initiation. The effect of KSR1 on tumor
initiating capacity was subsequently validated using in vivo extreme limiting dilution
analysis [155], KSR1 depletion caused a 70-fold reduction in tumor initiating cell
abundance in HCT116 cells (Vieira et al., unpublished results). In contrast, Anato2seq
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identified mRNAs whose translational efficiency was downregulated by KSR1
knockdown that were previously identified as tumor suppressive in nature (e.g., RUNX3
[156], LHX9 [157], FRMPD1 [158]). KSR1 knockdown upregulated NFATC2 mRNA
translation, which has been associated with stem cell formation [159, 160]. Therefore,
one possible explanation is that RUNX3, LHX9, FRMPD1, or NFATC2 may be playing
complementary mechanism adopted by the cancer cells to adapt and support cell growth
and survival in the absence of KSR1.
Among the seven candidate genes that were identified to be important for the
cancer-stem cell phenotype, the TE of DLL1 mRNA was the most significantly
downregulated in KSR1 knockdown cells. Cells expressing DLL1 represent a subset of
cancer stem cells and they are essential for tumor development and metastasis. Using
ALDH activity as a surrogate for identifying TICs, we found that transient knockdown of
DLL1 in HCT116 and SW480 cells decreased the tumor initiating capacity over 2-fold.
That KSR1 increases the TE of a subset of stem cell-related transcripts predicts a role
for KSR1 in regulating translation to drive TIC formation. Future experiments will be able
to determine the extent to which KSR1-scaffolded signaling contributes to tumor initiation
via the selective translation of transcripts important to CSC formation and the
mechanisms that lead to their preferential translation and enhanced function.
One limitation of this study is that the stable knockdown of KSR1 did not
decrease phosphorylation of 4EBP1 (Figure 3.3) as seen previously in the transient
knockdown of KSR1 or CRIPSR-targeted KSR1 knockout cells (Figure 3.1B). Although
the levels of phosphorylated 4EBP1 remain unchanged, KSR1 signaling may contribute
to the preferential loading of the polysomes in an 4EBP1-independent manner. The
exact mechanism by which KSR1 promotes the preferential translation of mRNAs
identified in the polysome profiling is still unexplored. Through this screen, it is evident
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that the role of KSR1-dependent ERK signaling is complex and vital to CRC translational
landscape and tumor progression.
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4. Chapter 4: KSR1- and ERK-dependent
translational regulation of EPSTI1 in colon
cancer cells

Portions of the material covered in this chapter are the subject of a manuscript published in eLife
by Rao et al [120].
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Introduction

Almost all CRC originates from epithelial cells lining the colon or rectum of the
gastrointestinal tract, but in order to invade the surrounding tissue, cancer cells lose cellcell adhesion, acquire motility, and become invasive, characterized by the epithelial-tomesenchymal transition (EMT), which is central to tumor pathogenesis [29, 30, 39, 161].
EMT is a complex cellular process during which epithelial cells lose polarity and cell-cell
contacts, and acquire mesenchymal characteristics. While EMT is crucial for cell
plasticity during embryonic development, transdifferentiation and wound healing, when
aberrantly activated EMT has deleterious effects, which facilitate motility and invasion of
cancer cells [26, 29, 39, 161]. EMT has been shown to be controlled by transcriptiondependent mechanisms, especially through repression of genes that are hallmarks of
the epithelial phenotype such as E-cadherin. Loss of E-cadherin at the membrane has
been associated with carcinoma progression and EMT [39-42]. E-cadherin is
transcriptionally repressed through the action of EMT transcription factors (TFs),
including Snail-family proteins (Snail1, Slug), zinc finger E-box binding homeobox 1 and
2 (Zeb1/2) and twist-related protein (Twist) [26, 162]. Transcriptional control of Ecadherin is unlikely to be the sole determinant of EMT, invasion and metastasis.
Induction of N-cadherin by epithelial cells known is to play a fundamental role during
initiation of metastasis [36, 50-55]. N-cadherin disassembles adherens junction
complexes, disrupting intercellular cohesion and reorienting the migration of cells, away
from the direction of cell-cell contact [50, 56]. Upregulation of N-cadherin promotes
motility and invasion [50-52, 57]. Thus, central to the process of EMT is the coordinated
loss of E-cadherin expression and the upregulation of N-cadherin gene expression,
termed cadherin switching [35, 36, 58-60].
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Previous studies have demonstrated transcriptional regulation of EMT through
oncogenic Ras or its downstream effector signaling pathways via the activation of EMTTFs [62, 64-68, 163]. Oncogenic Ras itself activates the EMT-TF Slug to induce EMT in
skin and CRC cells [66, 67]. Enhanced activity of ERK2 but not ERK1, has been linked
with Ras-dependent regulation of EMT [62, 163]. Several studies have also described an
alternative program wherein cells lose their epithelial phenotype, via post-transcriptional
modifications rather than transcriptional repression: this alternative program can involve
translational regulation or protein internalization [73, 74, 76]. Expression profiling of
polysome-bound mRNA to assess translational efficiency identified over thirty genes that
were translationally regulated upon Ras- and TGFβ- induced EMT [73, 74]. Functional
characterization of the resultant proteins should reveal preferentially translated mRNAs
essential to invasion and metastasis.
EPSTI1 was identified as a stromal fibroblast-induced gene using co-cultures of
breast cancer cells with stomal fibroblasts [164]. EPSTI1 is expressed at low levels in
normal breast and colon tissue but aberrantly overexpressed in breast tumor tissue [164].
EPSTI1 promotes cell invasion and malignant growth of primary breast tumor cells [165,
166]. We performed polysome profiling in CRC cells and found that KSR1 and ERK
induce EPSTI1 mRNA translation. EPSTI1 is both necessary and sufficient for coordinating
the up-regulation of N-cadherin with the downregulation of E-cadherin to stimulate cell
motility and invasion in CRC cells. These data demonstrate that ERK-regulated regulation of
mRNA translation is an essential contributor to the EMT-like phenotype and reveal a novel
effector of the cadherin switch whose characterization should yield novel insights into the
mechanisms controlling the migratory and invasive behavior of cells. We sought to
determine the functional relevance of KSR1-dependent induction of EPSTI1 to
phenotypic plasticity in CRC cells.
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Results

Polysome profiling analysis reveals that KSR1 knockdown suppresses EPSTI1
translation.
Combining gene targeting of KSR1 with polysome profiling in HCT116 and
HCT15 cell lines, we identified EPSTI1 as one of the highly significant mRNAs whose
translation decreased with decreased KSR1 expression (Figure 4.1A). EPSTI1 protein
expression was decreased with knockdown of KSR1 in HCT116 and HCT15 cells,
confirming that EPSTI1 protein accumulation is KSR1-dependent (Figure 4.1B), In
contrast, total EPSTI1 mRNA transcript was unchanged upon KSR1 disruption (Figure
4.1C, top panel). EPSTI1 TE was markedly decreased upon KSR1 depletion (Figure
4.1C, bottom panel). RT-qPCR analysis of sucrose-gradient fractions of monosome
mRNA and polysome RNA distribution confirmed that EPSTI1 mRNA shifted from
actively translating high molecular weight (MW) polysome fractions to low MW fractions
in KSR1 knockdown cells (Figure 4.1D, top panel). In contrast, HPRT1 mRNA was
insensitive in KSR1 knockdown in HCT116 and HCT15 cells, and qPCR analysis of
HPRT1 mRNA isolated from sucrose gradient fractions of control and KSR1 knockdown
cells showed no significant shift between the low MW and the high MW fractions (Figure
4.1D, bottom panel).
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Figure 4.1 KSR1 knockdown suppresses EPSTI1 mRNA translation in HCT116
and HCT15 cells.
(A) Identification that EPSTI1 TE is downregulated by KSR1 knockdown using
polysome profiling RNAseq followed by Anota2seq analysis in HCT116 and HCT15
cells [Fold change (|log2FC|) = 1.7 and P<.05. TE, translational efficiency. (B)
Western blot analysis of KSR1 and EPSTI1 following KSR1 knockdown in HCT116
and HCT15 cells. (C) RT-qPCR analysis of EPSTI1 mRNA in total RNA and
polysomal RNA (fractions number 6-8) in control and KSR1 knockdown HCT116 and
HCT15 cells. The TE was calculated as the ratio of polysomal mRNA to the total
mRNA (n=3; *, P <.05). (D) RT-qPCR analysis of (top) EPSTI1 and (bottom) HPRTI1
mRNA levels isolated from sucrose gradient fractions of control and KSR1
knockdown HCT116 and HCT15 cells. Fractions 3-5 (low MW) and 6-8 (high MW)
are plotted for the control and KSR1 knockdown state with values corresponding to
the percentage of total mRNA across these fractions n=3. Experiments shown in (A D) are representative of three independent experiments.
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KSR1 depletion does not affect EPSTI1 protein stability.
To rule out the possibility that KSR1 depletion affects EPSTI1 levels by
regulating protein stability, we first assessed EPSTI1 stability in control and KSR1
knockout HCT116 cells following treatment with a protein-synthesis inhibitor,
cycloheximide (CHX). The percent of EPSTI1 remaining was calculated in control and
KSR1 KO HCT116 cells. EPSTI1 expression is suppressed to 46% after 6 hours in
control (NT) HCT116 cells and to 52% in KSR1 depleted HCT116 cells from the
beginning of the treatment with CHX (Figure 4.2A). We analyzed EPSTI1 turnover using
a combination of a proteasome inhibitor, MG132, with and without the CHX treatment, in
control and KSR1 knockout HCT116 cells (Figure 4.2B). MG132 treatment did not
rescue the expression of EPSTI1 that was suppressed with CHX treatment in control
HCT116 cells. Also, EPSTI1 turnover was not sensitive to MG132 treatment in HCT116
cells lacking KSR1 expression. Therefore, in HCT116 cells, KSR1 depletion does not
cause proteosome-mediated degradation of EPSTI1. These data along with Anota2seq
analysis support our conclusion that EPSTI1 translation is induced by KSR1.

ERK signaling regulates EPSTI1 expression in CRC cells.
Treatment with the ERK inhibitor SCH772984 [167] suppressed EPSTI1 protein
expression in both CRC cell line HCT116 and tumorigenic patient derived colon organoid
engineered with K-RasG12D mutation and deletion of APC, p53, SMAD4 (KAPS) (Figure
4.3A) [111]. To determine if EPSTI1 expression is also dependent on mTOR signaling,
we tested the effect of the mTOR inhibition on EPSTI1 expression. The mTOR inhibitor
AZD8055 [168] robustly inhibited phosphorylation of mTOR substrate p70 S6 kinase and
decreased EPSTI1 expression in HCT116 cells (Figure 4.3B). These observations
suggest the mTOR inhibition affects EPSTI1 expression. While the total protein was
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Figure 4.2 Depletion of KSR1 in HCT116 cells does not affect EPSTI1 protein
stability.
(A) (Top) EPSTI1 and KSR1 levels were assessed by Western blot following
treatment with 10 µg/mL CHX for 0, 2, 4, and 6 hours in (left) control and (right)
KSR1 KO HCT116 cells. (Bottom) Levels of EPSTI1 protein at each time point (data
from two experiments in control and one experiment in KSR1 KO HCT116 cells). For
all conditions, the levels of EPSTI1 protein were quantified on a LICOR Odyssey.
EPSTI1 levels were normalized to Lamin B2 and represented relative to time 0. (B)
Representative Western blot images showing control and KSR1 KO HCT116 cells
treated with DMSO or 10 µM MG132 for 6 hours in the presence or absence of 10
µg/ml CHX for 6 hours. The levels of KSR1 or EPSTI1 protein were analyzed by
Western blot. Data shown in B are representative of at least two independent
experiments.
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reduced upon ERK inhibition in HCT116 cells, the EPSTI1 transcript levels were not
altered significantly by SCH772984 treatment (Figure 4.3C). RT-qPCR of the mRNA
isolated from low MW monosome fractions and high MW polysome fractions from
HCT116 cells treated with DMSO or ERK inhibitor demonstrated that EPSTI1 mRNA
shifted from high MW fractions to low MW fractions upon ERK inhibition (Figure 4.3D).
The distribution of mRNA for HPRT1 within the same profile was not altered by
SCH772984 treatment (Figure 4.3D).

KSR1 depletion suppresses ERK-dependent EPSTI1 protein expression in HCT116
cells.
To confirm our observations in KSR1 knockdown cells, we tested the effect of
CRISPR/Cas9-mediated targeting of KSR1 on EPSTI1 in CRC cell lines. EPSTI1 protein
expression was decreased upon KSR1 depletion in HCT116 and HCT15 cells and
EPSTI1 expression was restored in knockout cells upon expression of a KSR1
transgene (+KSR1) (Figure 4.4A). Re-expression of KSR1 in CRISPR-targeted HCT116
cells with the DEF domain mutant that cannot bind ERK (AAAP) failed to restore the
expression of EPSTI1 (Figure 4.4B). These data indicate that KSR1-dependent ERK
signaling is a critical regulator of EPSTI1 mRNA translation in CRC cells and organoids.

EPSTI1 knockdown suppresses anchorage-independent growth in CRC cells.
We showed previously that KSR1 expression is upregulated in CRC cell lines
when compared to the non-transformed human colon epithelial cells (HCECs) [16]. We
observed that EPSTI1 protein is aberrantly expressed in CRC cell lines HCT116 and
HCT15, while its expression is detected in low levels in HCECs (Figure 4.5A).
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Figure 4.3 ERK inhibition suppresses EPSTI1 protein expression in cell lines
and organoids.
(A) Western blot of the indicated proteins in HCT116 cells (top) and KAPS quadruple
mutant colon organoids (bottom) treated with DMSO or 1 µM SCH772984 (ERKi) for
48 hours. (B) EPSTI1 protein expression was analyzed by Western blot in HCT116
cells treated with DMSO, 1 µM SCH772984 (ERKi), or 1 µM AZD8055 (mTORi) for
48 hours. (C) RT-qPCR analysis of EPSTI1 mRNA from total RNA in HCT116 cells
treated with either DMSO or SCH772984 (n=3; ns, non-significant). (D) RT-qPCR
analysis of EPSTI1 and HPRT1 mRNA levels in LMW (fractions 3-5) and HMW
(fractions 6-8) of the DMSO control or SCH772984 (ERKi)-treated HCT116 cells
(n=3; *, P<.05; ***, P<.001). All values displayed as mean ± S.D. Experiments shown
in (A - D) are representative of three independent experiments. Figure 4.3A was
completed in collaboration with Lisa Humphrey-Brattain and Dr. Adrian Black.
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expressing KSR1 mutant deficient in binding ERK (KSR1 KO + KSR1 AAAP).
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EPSTI1 protein expression is also modestly higher in quadruple mutant colon (KAPS)
organoids than normal colon organoids (Figure 4.5A).
To assess if EPSTI1 is required for CRC cell viability, we performed siRNA
knockdown of EPSTI1 in HCT116 and HCT15 cells. EPSTI1 disruption suppressed
viability on poly-(HEMA) coated plates by 40% in HCT15 cells, and over 70%, in
HCT116 cells (Figure 4.5B). EPSTI1 knockdown reduced colony formation in soft agar
by 63% in HCT116 cells and 71% in SW480 cells (Figure 4.5C). These observations
show that KSR1-dependent translation of ESPTI1 is required for anchorage-independent
growth of CRC cell lines.

KSR1 or EPSTI1 disruption decreases cell motility in CRC cells.
Considering the suggested role of EPSTI1 in promoting the EMT-like phenotype
[164, 165], we sought to evaluate the biological role of EPSTI1 in CRC cells. The motility
of control and EPSTI1 knockdown HCT116 cells was analyzed by taking time-lapse
images of scratch wounds and measuring the relative wound density (percent wound
density) over 72 hours [169] (Figure 4.6A). IncuCyte® software was used to calculate
relative wound density, i.e., the percentage of spatial cell density inside the wound
relative to the spatial density outside of the wound area at a given time point. The
calculation of cell migration using this method, avoids false changes in cell density due
to proliferation. Motility was also assessed in control, CRISPR-targeted (KSR1 KO), and
CRIPSR-targeted HCT116 cells expressing KSR1 (KSR1 KO + KSR1) (Figure 4.6B).
Cells lacking either EPSTI1 or KSR1 expression were approximately 20% less motile
compared to control cells (Figure 4.6A-B). Reintroduction of KSR1 expression in
CRISPR-targeted HCT116 cells restored motility comparable to the control cells (Figure
4.6B). EPSTI1 knockdown HCT116 and SW480 cells were subjected to Transwell
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invasion assays. EPSTI1 knockdown suppresses cell invasion through Matrigel® by 72%
in HCT116 and by 75% in SW480 cells. (Figure 4.6C). Since KSR1 is required for
EPSTI1 translation, we determined the functional contribution of KSR1 in regulating cell
invasion. KSR1 depletion suppressed invasion by 64% in HCT116 and by 53% in
SW480 cells (Figure 4.6D). Overall, these results suggest that KSR1-dependent
EPSTI1 signaling contributes to cell migration and invasion in CRC cells.

KSR1 or EPSTI1 disruption causes cadherin switching in CRC cells.
To understand the underlying mechanism by which KSR1 and EPSTI1 promote
motility and invasion in CRC cells, we evaluated their contribution to the expression of
critical determinants of EMT that modulate cell adhesion, E- and N-cadherins and EMTTFs. Compared to the non-targeting control, KSR1 depletion in HCT116, HCT15 and
SW480 cells resulted in elevated levels of E-cadherin, along with a coincident decrease
in EMT-TF Slug (Figure 4.7A). KSR1 depletion resulted in modest increase in the
expression of Vimentin while the expression of Snail1 was not changed in KSR1
knockout HCT116 cells (Figure 4.7B). Upon knockdown of EPSTI1 with either of two
siRNA oligonucleotides in HCT116 and SW480 cells, we observed a decrease in the
expression of N-cadherin, Zeb1 and Slug (Figure 4.8A). Coincident with the decrease in
EMT-TFs, E-cadherin levels were generally elevated (Figure 4.8A). While there was no
significant change in Slug and Zeb1 mRNA upon EPSTI1 knockdown (Figure 4.8B),
EPSTI1 disruption decreased N-cadherin mRNA expression over 50% in HCT116 and
SW480 cells (Figure 4.8B).
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Figure 4.7 KSR1 disruption suppresses E-cadherin expression in CRC cells.
(A) Western blot analysis of the cell lysates prepared from control and two clones of
CRISPR-targeted HCT116, SW480, and HCT15 cells (KSR1 KO) for E-cadherin,
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Figure 4.8 EPSTI1 knockdown decreases N-cadherin mRNA and protein levels
in CRC cells.
(A) Western blot of Zeb1, Slug, E-cadherin, and N-cadherin in HCT116 and SW480
cells 72 hours following EPSTI1 knockdown. (B) RT-qPCR analysis of EPSTI1
mRNA (top-left), N-cadherin mRNA (bottom-left), Slug mRNA (top-right) and Zeb1
(bottom-right) following knockdown of EPSTI1 for 72 hours in HCT116 and SW480
cells. n=6; ***, P<.001; ****, P<.0001. Western blots shown in (A), and qPCR results
shown in (B) are representative of at least three independent experiments.
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ERK mediates EPSTI1-dependent N-cadherin expression.
Enhanced activity of ERK2 and not ERK1 has been linked with Ras-dependent
regulation of EMT [62]. The binding of FRA-1 via its DEF domain [95] to phosphorylated
ERK2 promoted EMT-TF Zeb protein expression or vimentin expression, and increased
cell motility and invasion in breast cancer cells [62, 64]. We tested the effects of ERK1 or
ERK2 knockdown on EPSTI1 and N-cadherin expression. Knockdown of either ERK1 or
ERK2 in SW480 cells for 72 hours suppressed EPSTI1 expression effectively when
compared to control SW480 cells (Figure 4.9). N-cadherin expression was robustly
decreased in ERK2 knockdown SW480 cells. These data suggest the possibility that
both ERK1 and ERK2 affect EPSTI1 signaling in SW480 cells.

Upregulation of N-cadherin in cells lacking EPSTI1 expression rescues
invasiveness in HCT116 cells.
Following EPSTI1 knockdown, we subjected control HCT116 cells and HCT116
cells overexpressing N-cadherin to Transwell invasion assays through Matrigel®. EPSTI1
knockdown suppressed cell invasion. The expression of N-cadherin in cells lacking
EPSTI1 was sufficient to restore invasiveness to HCT116 cells (Figure 4.10). This is
consistent with previous observations that upregulation of N-cadherin expression
enhances motility in multiple cancer cell lines [50, 57, 170]. These results indicate that
the switch from E-cadherin to N-cadherin expression promotes the progression of
migratory and invasive behavior orchestrated by EPSTI1 signaling in CRC cells.
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EPSTI1 is necessary and sufficient for the EMT-like phenotype in CRC cells.
To determine the extent to which KSR1- and ERK-dependent EPSTI1 translation
is critical to colon tumor cell growth and invasion, we expressed a MSCV-FLAG-EPSTI1GFP construct in KSR1-CRISPR knockout HCT116, SW480, and HCT15 cells.
CRISPR/Cas9-mediated deletion of KSR1 disrupted EPSTI1 expression, downregulated
Slug and N-cadherin expression and elevated E-cadherin expression in HCT116 and
SW480 cells (Figure 4.11A). The effect of KSR1 knockout on Slug, N-cadherin, and Ecadherin was modest in HCT15 cells (Figure 4.11A). E-cadherin staining was absent in
control CRC cells but evident at the cell membrane in KSR1 KO cells (Figure 4.11B).
Exogenous expression of EPSTI1 in cells lacking KSR1 restored the cadherin switch, by
decreasing the expression of E-cadherin (Figure 4.11A and 4.11B) and increasing Ncadherin levels in HCT116 and SW480 cells comparable to control cells (Figure 4.11A).
Suppression of E-cadherin and restoration of N-cadherin expression by the EPSTI1
transgene reestablished the ability of KSR1 knockout cells to migrate in monolayer
culture (Figure 4.12A) and invade through Matrigel®. Forced expression of EPSTI1 in
these cells, increased the number of invading cells by over three-fold (Figure 4.12B).

EPSTI1 does not impact cell proliferation in CRC cells.
To ascertain that the effect of EPSTI1 knockdown or the forced expression of
EPSTI1 in KSR1 CRISPR-targeted cells on migration and invasion are not influenced by
the effect of KSR1 or EPSTI1 on cell proliferation, we analyzed the cell growth kinetics in
CRC cell lines. To determine the effect of EPSTI1 on cell proliferation, we analyzed the
cell growth kinetics in HCT116 and SW480 cells (Figure 4.13). Over three days, EPSTI1
knockdown had no effect on cell proliferation compared to control HCT116 and SW480
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significant effect on cell proliferation for 24 hours in HCT116 and SW480 cells (Figure
4.13A-B), EPSTI1 expression increased the number of invading cells in that period over
50% in HCT116 and over 70% in SW480 cells (Figure 4.12B). Although rescue of
EPSTI1 expression in KSR1 depleted cells had a significant effect on cell proliferation
over 7 days compared to KSR1 knockout in HCT116 and SW480 cells (Figure 4.14B),
EPSTI1 expression rescued migratory potential by over 60% in KSR1 depleted HCT116
and SW480 cells within 24 hours (Figure 4.12A). These data reveal that disabling the
cadherin switch and inhibition of cell invasion by KSR1 disruption interrupts EPSTI1
translation, highlighting the pivotal role of this pathway for the induction of EMT-like
phenotype in CRC cells.

EPSTI1 expression enhances N-cadherin levels in non-transformed colon
epithelial cells and in CRC cells lacking KSR1 expression.
Knockdown of EPSTI1 in HCT116 and SW480 cells decreased N-cadherin
mRNA expression by 50% (Figure 4.8B). Upon KSR1 depletion, N-cadherin mRNA
decreased 32% in HCT116 and 89% in SW480 cells (Figure 4.15A). Ectopic expression
of EPSTI1 in these cells restored the N-cadherin mRNA expression to levels observed in
control SW480 cells, while in HCT116 KSR1 KO, forced EPSTI1 expression increased
N-cadherin mRNA levels 3-fold above that seen in control HCT116 cells (Figure 4.15A).
We tested the effect of ectopic expression of EPSTI1 on invasion in non-transformed
HCECs. We stably expressed MSCV-IRES-GFP or MSCV-IRES-EPSTI1-GFP in HCECs
and subjected the cells to Transwell invasion assay through Matrigel® (Figure 4.15C)
and observed that EPSTI1 alone was sufficient to dramatically induce the expression of
N-cadherin and double the invasive activity of HCECs (Figure 4.15D). These data
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(A) Cell proliferation growth curves in control (blue), KSR1 KO (red) HCT116 (upper
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indicate that EPSTI1 mediates the expression of N-cadherin to promote invasive
behavior in non-transformed colon epithelial cells and CRC cells.

EPSTI1 expression reverses growth inhibition in KSR1 KO CRC cells.
The E- to N-cadherin switch promotes cancer cell survival following the loss of
cell adhesion to the extracellular matrix (65, 66). KSR1 also promotes CRC cell survival
when detached from a solid substrate (6, 18). To determine the extent to which EPSTI1
expression was sufficient to restore CRC cell viability in the absence of KSR1, we grew
cells under anchorage-independent conditions either on Poly-(HEMA) (Figure 4.16A) or
on soft agar (Figure 4.16B) following forced expression of EPSTI1 in HCT116, HCT15,
and SW480 cells lacking KSR1. Anchorage-independent viability was measured over
three days on poly-(HEMA) coated plates. Compared to control HCT116 and HCT15
cells, viability decreased approximately 75% in cells lacking KSR1. Ectopic expression of
EPSTI1 restored viability to approximately 50% of control levels in both cell lines (Figure
4.16A). Similar to our previous findings (6, 56), KSR1 disruption hampered the ability of
Ras transformed cells to form colonies on soft agar, with the number of colonies formed
in HCT116 and SW480 cells dramatically decreasing by 75% in the absence of KSR1.
Forced expression of EPSTI1 was sufficient to reverse the deficit in colony formation
caused by KSR1 disruption to levels observed in control HCT116 and SW480 cells
(Figure 4.16B). These results show that despite the absence of KSR1 to maintain and
support cell growth, ectopic EPSTI1 expression was able to maintain anchorageindependent viability in CRC cells.
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(+EPSTI1). (n=3), **, P <.01; ***, P <.001; ****, P <.0001 (B) Western blot analysis of
EPSTI1 and N-cadherin from the cell lysates prepared from Wild-type (WT) HCEC,
HCECs transfected with MSCV-IRES-GFP (IRES-GFP) or MSCV-FLAG-EPSTI1IRES-GFP (EPSTI1-GFP). (C) Wild-type (WT) HCEC, HCECs transfected with
MSCV-IRES-GFP (IRES-GFP) or MSCV-FLAG-EPSTI1-IRES-GFP (EPSTI1-GFP)
were subjected to Transwell migration assays through Matrigel®. The number of
invaded cells per field was determined, (n=4); ***, P <.001. Representative
microscopic images of the respective cells following invasion through Matrigel® are
shown (Bottom panels).
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Figure 4.16 EPSTI1 expression in KSR1 KO CRC cells restores anchorageindependent growth in CRC cells.
(A) Control, KSR1 KO HCT116 and HCT15 cell viability (CellTiter-Glo) on poly(HEMA)-coated plates at the indicated days with or without EPSTI1 (KSR1 CRISPR
+ EPSTI1) expression. The data are shown as relative luminescence units mean ±
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Data were analyzed for statistical significance one-way ANOVA followed by t test.
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EPSTI1 is aberrantly expressed in colon tumor tissue compared to normal tissue.
Analysis of EPSTI1 expression in normal and tumor colon tissue from publicly
available databases supports the role of EPSTI1 contributing to tumorigenesis. The
Cancer Genome Atlas (TCGA) shows a significant upregulation of EPSTI1 mRNA
across all the stages of colon adenocarcinoma (Figure 4.17A). Clinical Proteomic Tumor
Analysis (CPTAC) data indicate that EPSTI1 protein is upregulated significantly in stage
2 of colon cancer compared to other stages (Figure 4.17B). These data extend our
study showing a discordance between protein and mRNA expression in colon tumors.
Furthermore, these data indicate that a post-transcriptional mechanism of EPSTI1
mRNA is likely to influence its protein expression levels. Stage 2 is characterized by full
thickness invasion of either the second or third layer of the bowel wall without the
lymphovascular invasion (NCCN guidelines). Overexpression of EPSTI1 is associated
with samples derived from stage 2 CRC. Although it remains to be demonstrated, it is
tempting to speculate that EPSTI1 expression in stage 2 is necessary for invasive
migration. Overall, these results suggest that induction of EPSTI1 during progression of
CRC may lead to enhanced invasiveness with the progression to EMT and metastasis.
Further studies are necessary to determine whether EPSTI1 expression resides
predominantly in the leading edge of the invading cells and delineate the mechanism by
which EPSTI1 regulates EMT progression in CRC.

Discussion

Persistent oncogenic reprogramming of transcription and translation during EMT
grants migratory and invasive properties to tumor cells [26, 161]. Multiple studies have
established a relationship between oncogenic Ras-mediated ERK signaling and EMT,

88

Transcript per million

A

EPSTI1 RNA expression in COAD

150
100

****
****

****

****

50

Normal
Stage 1
Stage 2
Stage 3
Stage 4

0
Normal Stage 1 Stage 2 Stage 3 Stage 4

B

EPSTI1 protein expression in COAD

Z value

2

**

0

Normal
Stage 1
Stage 2
Stage 3
Stage 4

-2
Normal Stage 1 Stage 2 Stage 3 Stage 4

Figure 4.17 EPSTI1 RNA and protein expression across individual CRC stages
(A) Expression of EPSTI1 in normal and individual stages of colon adenocarcinoma
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stages of colon cancer form CPTAC (**, P <.005).
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either through Ras or its downstream effector signaling pathways activating EMT-TFs
[62-68]. Silencing of Erbin, a tumor suppresser known to disrupt the KSR1-RAF1
interaction, promoted cell migration and invasion of CRC cells, but did not identify the
effectors of KSR1-dependent MAPK signaling affecting EMT [72]. Mediators of the EMTlike phenotype that activate cap-dependent translation initiation have been associated
with increased aggressiveness and metastases of cancer cells, and we have shown that
KSR1 can affect translation initiation [73-75, 98].
Our observations establish the novel role of the scaffold protein KSR1 promoting
the preferential translation of an EMT-related gene, EPSTI1, and outline a mechanism
for KSR1-dependent stimulation of phenotypic plasticity. Using gene expression analysis
of the polysome-bound mRNA, we discovered that KSR1 and ERK increase the
translational efficiency of EPSTI1 mRNA. EPSTI1 mediates KSR1-dependent motility,
invasion, and anchorage-independent growth coincident with an increase of Slug
expression and decreasing E-cadherin expression. EPSTI1 knockdown also decreased
the expression of N-cadherin mRNA and protein. In the absence of KSR1, ectopic
expression of EPSTI1 was sufficient to suppress E-cadherin expression, stimulate Ncadherin expression and enhance motility and invasive behavior, this invasive behavior
was also induced in non-transformed colon cells. These data demonstrate that a KSR1and ERK-regulated component is critical to the execution of the transcriptional program
that drives interconversion between epithelial and mesenchymal phenotypes. These
studies of post-transcriptional regulation and mRNA translation reveal the importance of
expanding beyond gene expression analysis for detecting mechanisms underlying
epithelial plasticity and tumorigenicity.
The association of EPSTI1 with tumor metastatic potential is supported by
observations that EPSTI1 is highly upregulated in invasive breast cancer tissues.
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EPSTI1 thus appears to play an important role in promoting metastasis, tumorsphere
formation, and stemness [164-166]. Although the aberrant expression of EPSTI1 in
breast cancer cells is well-established, there is little indication in the literature of the
mechanism how EPSTI1 induces EMT, cancer invasion, and metastasis. EPSTI1dependent induction of invasion in breast cancer cells was attributed to increased
expression of Slug and Twist mRNA and increased expression of fibronectin and α2β1
integrins [166]. Another study suggested the interaction of EPSTI1 with valosin-containing
protein (VCP) and the subsequent activation of NF-κB signaling contributed to the increased
tumor invasion and metastasis [165]. Future studies should evaluate the potential of EPSTI1
to directly affect N-cadherin and EMT-TF expression, assess the role of NF-κB signaling in
EPSTI1-dependent CRC cell EMT and evaluate the potential of EPSTI1 to contribute to
invasion and metastasis in vivo.
Determining how KSR1- and ERK-dependent signaling promotes EPSTI1
translation may yield novel mechanisms underlying tumor cell metastatic behavior. We
show that EPSTI1 mRNA is unchanged upon KSR1 disruption or ERK inhibition
(Figures 4.1 and 4.3) and KSR1 depletion does not affect the turnover of EPSTI1
protein (Figure 4.2), suggesting that KSR1 regulates EPSTI1 through posttranscriptional modifications enhancing its preferential loading onto the polysomes.
Differential mRNA splicing is implicated in EMT-related processes and splicing
regulatory factors have been implicated in the motility and invasive behavior of tumor
cells [88, 171]. One possibility is that KSR1 signaling promotes the splicing of EPSTI1
that promotes its preferential translation contributing to increased motility and invasion.
Upon removal of KSR1 or EPSTI1, the tumor cells switch back from a highly
migratory and invasive EMT-like state to the epithelial state. However, the invasive
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property is not completely lost following KSR1/EPSTI1 disruption (Figure 4.6B), which
could be attributed to other mesenchymal markers retained in the cells, such as vimentin
(Figure 4.7B). Investigating other EMT-related mRNAs that are preferentially translated
in response to KSR1-scaffolded ERK signaling may reveal additional mRNAs that make
previously unappreciated contributions to cell migration, invasion, and EMT. Constitutive
KSR1 or EPSTI1 knockout yields developmentally normal mice [122, 172, 173]. While
KSR1 or EPSTI1 may not be essential to EMT during normal development, they may
play a role in other EMT-dependent events such as wound healing where cells
collectively migrate, differentiate, and re-epithelialize around and/or within the damaged
site. If their role in EMT is exclusive to tumor cells it will reveal a key vulnerability for
therapeutic evaluation. Further characterization of KSR1, EPSTI1 and the additional
effectors repurposed by dysregulated translation in CRC should reveal additional novel
mechanisms critical to CRC tumor survival and progression.
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5. Chapter 5: KSR1 signaling promotes
splicing of EPSTI1 contributing to the
epithelial-to-mesenchymal transition

Portions of the material covered in this chapter are the subject of a manuscript in preparation by
Rao et al.
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Introduction

The regulation of protein synthesis occurs at multiple levels and involves intimate
connection between transcription and RNA processing. All steps in RNA processing
including RNA synthesis, pre-messenger RNA (pre-mRNA) splicing, intracellular
transport, translation, and degradation, involve complex and regulated processes that
are mediated by RNA binding proteins (RBPs) that bind RNA to control its biogenesis
and function [174]. pre-mRNA splicing is an essential process that involves removal of
introns and inclusion or exclusion of exons from nascent pre-mRNA to produce mature
RNA [175]. Unlike constitutive splicing, that involves removal of introns and exon ligation
of the exons in the order in which they appear in a gene; alternative splicing (AS) allows
the selective inclusion or skipping of exonic or intronic sequences from a pre-mRNA.
Thereby AS increases the coding capacity of genes and enables the synthesis of
structurally and functionally distinct protein isoforms. Each AS event is controlled by
multiple RBPs, creating a cell-type specific distribution of alternatively spliced products.
These dynamic RNA-protein complexes have remarkable plasticity in substrate
recognition and can influence proteins bound to pre-mRNA to produce multiple mRNA
isoforms [176, 177].
Splicing factors (SFs) are a class of RBPs frequently altered in human diseases,
leading to changes in the spliced isoform repertoire of target genes [87, 178, 179]. SFs
are critical components of global gene expression and interact with unspliced and mature
mRNAs to regulate all aspects of cell growth and development. Activator and repressor
SFs bind specific sequences on their target pre-mRNAs and elicit concentration-dependent
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effects on splicing. Increased SFs levels can expand the exonic and intronic target
sequences available, directly affecting the splicing of target exons by recruiting or
repelling the splicing machinery. SF binding can limit the accessibility of another RBP
that normally would repress or activate the AS of that specific exon and thus elicit the
opposite effect. Conversely, decreased SF levels will also affect the splicing of its targets
by limiting its ability to bind target exons and by freeing SF binding sites, which can be
occupied by other RBPs. These observations have implications for normal cellular
homeostasis and disease, including cancer. Transient changes in splicing-factor level,
stability, or function can alter splicing to affect cell phenotype. [87, 88, 171, 178, 180182].
Cancer associated mis-splicing and post-transcriptional mechanisms reconfigure
the proteome to control the cancer cell phenotypes [87, 88, 179]. AS is a key step in
post-transcriptional regulation that tightly balances cell identity between epithelial mesenchymal states and during stem cell differentiation [88]. Several studies have
documented an intricate connection between changes in AS and epithelial-tomesenchymal transition (EMT) activation [88, 171, 183, 184], highlighting how
dysregulated AS could be a trigger for tumor relapse and metastatic spread, dramatically
affecting patient outcome. Our current knowledge likely represents only the tip of the
iceberg in terms of the many mechanisms by which AS impacts oncogenic signaling.
Therefore, there is a need to identify amongst the thousands of splicing alterations those
that significantly contribute to tumor formation and progression.
SRSF9 is a member of Serine/Arginine-Rich (SR) proteins family of SFs (SRSF1 to
12) that act at multiple steps of spliceosome assembly, contributing to both constitutive
and alternative splicing [87, 182, 185]. SR proteins have a modular structure consisting of
one or two RNA-recognition motif that determine their RNA-binding specificity, followed by a
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C-terminal domain rich in alternating serine and arginine residues (RS domain). Although
SR proteins were initially described as activators promoting exon inclusion,
transcriptomic studies suggest that they can promote inclusion for some targets and
skipping for others [186]. SRSF9 displays a strong enrichment for the AGSAS motif (S=
G or C) and is involved a wide range of functions, for example, inclusion of SMN exon 7
[187, 188] and tau exon 10 [189], repressor of 3’ splice site selection of CE9 [190],
exclusion of CASP2 exon 9 and CD44 exon 10 [191, 192], and 5’ splice-site utilization of
Bcl-xL [193]. In CRC cells, SRSF9 was shown to promote ß-catenin protein synthesis
and stimulate tumor growth in vitro and in vivo [194]. Although changes in several SFs
have been shown to play a role in EMT-related process [88], how SRSF9 contributes to
EMT during healthy development as well as in diseases remains to be determined.
We have previously reported that in human CRC cells KSR1-dependent signaling
is required for the EMT-like phenotype [120]. We combined targeting of genes encoding
key effectors of Ras signaling with polysome profiling to discover that KSR1 upregulates
the translational efficiency (TE) of EMT-related transcripts. One of these targets,
Epithelial Stromal Interaction 1 (EPSTI1), mediates Ras and KSR1-dependent induction
of the switch in CRC cells from E-cadherin to N-cadherin [120], a central hallmark of EMT
[36, 195], and anchorage-independent growth. In this study, we identified a novel KSR1dependent signal promoting the stability of SRSF9. We show that SRSF9 also controls
the E- to N-cadherin switch and is required for CRC cell migration and invasion in vitro.
SRSF9 associates with EPSTI1 mRNA and a specific splice form of EPSTI1 is optimal
for induction of CRC cell EMT, suggesting that SRSF9-mediated splicing of EPSTI1 may
be a Ras-induced and KSR1-mediated mechanism driving CRC motility and invasion.
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Results

KSR1 disruption suppresses SRSF9 expression in CRC cells
We demonstrated that KSR1-mediated signaling regulates the translational
landscape of human CRC cells to support their survival [98, 120]. We have recently
shown that translation of EPSTI1 and other mesenchymal mRNAs is promoted by Rasmediated KSR1/ERK signaling. RBPs can direct mRNA transcripts onto polysomes and
promote their translation to protein. To identify post-transcriptional regulators of KSR1dependent translation control of EMT, we used the computational tool PRADA
(Prioritization of Regulatory Pathways based on Analysis of RNA Dynamic Alterations)
[116] developed by Dr. Goodarzi’s group that identifies RNA-binding proteins through the
systematic detection of coordinated changes in their target RBPs. PRADA uses gene
expression representations of RBP binding sites to scan the target sequences of interest
for the presence or absence of matches. Since many RBPs fall into families with highly
similar binding preferences, PRADA analysis introduced an additional penalty term that
excludes RBPs whose activity is unchanged in the analysis, which extends and
stabilizes the lasso regression model. Polysome profiling RNAseq analysis in HCT116
and HCT15 cells with and without KSR1 knockdown identified 98 mRNAs whose
translation was altered due to depletion of KSR1. We applied PRADA to the RNAseq
dataset and identified RBPs that had predicted binding sites in KSR1-dependent
mRNAs. PRADA predicted sequence matches to several RBP-binding sites (Figure
5.1A). Among the top eight RBPs predicted by PRADA to bind KSR1-dependent
mRNAs, the size, and the direction of the coefficient assigned to SRSF9-binding sites
were disproportionately decreased in the absence of KSR1. The top candidate SRSF9
shares binding motifs similarities and targets with other SR family members, yet none of
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the other SR proteins including SRSF1, SRSF2, SRSF7 or SRSF10 were significantly
associated with KSR1-dependent mRNAs. Analysis of SRSF9 transcript and protein
levels in normal and tumor colon tissue from publicly available databases (i.e., TCGA
and CPTAC) supports a link between SRSF9 and tumorigenesis, with a significant 2-fold
upregulation of both mRNA and protein expression in colon adenocarcinoma compared
to adjacent normal tissue (Figure 5.1B). We thus tested the effect of KSR1 depletion on
SRSF9 in CRC cell models. CRIPSR-mediated KSR1 knockout (KO) in HCT116 cells
lead to decreased SRSF9 protein expression, and the expression of SRSF9 was
restored in KO cells upon re-expression of a KSR1 from a cDNA construct (Figure
5.1C). Treatment of tumorigenic patient derived colon organoids engineered with
deletion of APC, p53, and SMAD4 and K-RasG12D mutation (KAPS) with ERK inhibitor
SCH772984 [167] led to a modest decrease in SRSF9 protein expression in (Figure
5.1D). These results suggest that ERK and KSR1 activity are crucial for SRSF9
expression in colon tumor cells and organoids.

Depletion of KSR1 affects SRSF9 degradation.
To assess how KSR1 regulates SRSF9 levels, we first investigated whether it
directly impacts its mRNA expression. SRSF9 transcript levels were measured in control
and KSR1 knockdown HCT116 cells (Figure 5.2A), as well as in control and KSR1 KO
HCT116 or SW480 cells (Figure 5.2B). Depletion of KSR1 did not affect total SRSF9
mRNA expression in both HCT116 or SW480 cells, nor the polysome-bound SRSF9
fraction in HCT116 cells (Figure 5.2A-B). SR proteins are also regulated posttranslationally. Indeed, the RS domain of SR proteins is extensively phosphorylated on
serine residues, and the RS domain regulates SF subcellular localization and SF activity.
SR proteins are also modified by the covalent attachment of polypeptides such as
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Figure 5.1 KSR1 depletion in HCT116 cells or ERK inhibition in quadruple
mutant organoids suppresses SRSF9 expression.
(A) SRSF9 interaction with differentially translated mRNAs in HCT116 and HCT15
cells is suppressed by KSR1 knockdown. Regression coefficients of the indicated
RBP as set by PRADA and the top eight coeffients are shown as function of l1 norm,
i.e., sum of the magnitude of all the coefficients (n=3) (B) RNA and protein
expression of SRSF9 in normal and colon adenocarcinoma (COAD) from (top) TCGA
and (bottom) CPTAC obtained by the UALCAN portal and plotted using GraphPad
Prism. ****, P <.0001 (C) Western blot analysis of KSR1 and SRSF9 in HCT116 cells.
(D) Western blot analysis of phospho-RSK (S380), RSK, and SRSF9 in colon tumor
organoids (KAPS) treated with and without ERK inhibitor 1 µM SCH772984 for 48
hours. Figure 5.1A was completed in collaboration with Siddesh Southekal.
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ubiquitin (Ub), and these Ub chains can target SR proteins for degradation by the 26S
proteasome. The PhoshoSitePlus database [196, 197] identified Lys28 and Lys36 as
two potential ubiquitination sites in SRSF9. On the basis of these observations, we
tested whether depletion of KSR1 promotes SRSF9 degradation. SRSF9 levels were
rescued upon MG132 treatment in KSR1 KO HCT116 cells, indicating that KSR1
contributes to stabilization of SRSF9 (Figure 5.2C). We also examined SRSF9 turnover
in HCT116 cells following treatment with the protein synthesis inhibitor cycloheximide
with and without KSR1 KO (Figure 5.2D). In control HCT116 cells, the half-life of SRSF9
was determined to be 5.5 hours. KSR1 KO cells had lower SRSF9 levels at 0 hour
compared to the control HCT116 cells and the levels of SRSF9 decreased rapidly after
the addition of cycloheximide, with only 40% of the protein remaining after 2 hours.
Together, with these results suggest that KSR1 prevents the degradation of SRSF9 in
CRC cell lines.

SRSF9 depletion suppresses CRC cell motility and invasion.
SRSF9 was shown to promote cell invasion and migration but did not impact cell
proliferation or cell death in breast cancer models [171]. Given that KSR1 regulates the
migration and invasion in CRC cells, we hypothesized that SRSF9 functions to
phenocopy KSR1 in CRC cells. To test this possibility, we knocked down SRSF9
expression in HCT116 and SW480 cells using siRNA (Figure 5.3C) and subjected the
cells to in vitro migration and invasion assays [120]. SRSF9 knockdown significantly
impaired migration by over 50% in HCT116 and SW480 cells (Figure 5.3A). In Transwell
invasion assays through Matrigel, SRSF9 knockdown significantly suppressed invasion
by over 75% in HCT116 and SW480 cells (Figure 5.3B). Consistent with these data,
SRSF9 knockdown inhibited N-cadherin expression with a coincident increase Ecadherin expression in HCT116 cells (Figure 5.3D). These data reveal a novel KSR1-
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Figure 5.2 KSR1 depletion affects SRSF9 turnover in HCT116 cells.
(A) RT-qPCR analysis of SRSF9 mRNA from total RNA and polysomal RNA
(fractions number 6-8) in control (shMC1) and KSR1 knockdown (shKSR1) HCT116
cells, data are shown as the ratio of polysomal mRNA to the total mRNA (n=3; ns,
non-significant). (B) RT-qPCR analysis of SRSF9 mRNA from total RNA in control
and KSR1 KO HCT116 cells or SW480 (n=3; *, P<.05; ns, non-significant) (C)
SRSF9 protein levels in control and KSR1 KO HCT116 cells were treated with (+) or
without (-) 10 µM proteosome inhibitor MG132 for 6 hours and measured by Western
blot, using β-actin as the loading control (D) (Left) Control and KSR1 KO HCT116
cells were treated with 10 µg/mL cycloheximide (CHX) for the indicated times.
SRSR9 and β-actin were detected by Western blot. (Right) SRSF9 expression at 0
hour was normalized to 100% and SRSF9/β-actin was quantified on a LICOR
Odyssey. Data shown here are representative of at least two independent
experiments.
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dependent signaling pathway regulating SRSF9 and playing a role in the EMT-like
phenotype in CRC cells.

KSR1 knockdown causes mRNA with differentially spliced exons to accumulate in
polysomes.
We analyzed AS changes between control and KSR1 knockdown HCT116 and
HCT15 cells using RNAseq from total and polysome-bound fractions. Differentially
spliced events (DSEs) were quantified in our polysome profiling RNA-seq data using
rMATS 4.1.0 [198], a computational tool for differential splicing analysis that uses both
exonic and intronic reads to quantify a Percent Spliced In (PSI) value for each AS event.
We identified >100 AS events in HCT116 and HCT15 cells using cut-offs |ΔPSI|>10%
and FDR < 0.05 with at least >5 reads per AS event. Comparison of DSEs between total
and polysomal mRNA demonstrated that KSR1 depletion enhanced the accumulation of
transcripts with included and skipped exons in polysomes in HCT15 cells and
accumulation of skipped exons in polysomes in HCT116 cells (Figure 5.4). EPSTI1 has
three different transcript variants because of splicing of alternative exons yielding
different products. It is possible that KSR1 may be regulating the balance between
specific EPSTI1 splicing isoforms and that one of these isoforms may be selectively
translated to enhance motility, invasion, and EMT. Because of inadequate sequencing
depth, EPSTI1 was not detected as one of the significantly spliced genes in the rMATS
analysis. These results indicate that pre-mRNA splicing plays a role in the increased
loading of specific transcripts onto the polysomes in a KSR1-dependent manner.
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Figure 5.3 SRSF9 knockdown suppresses migration, invasion and N- to Ecadherin switching.
(A) Control or SRSF9 knockdown (siSRSF9) in HCT116 and SW480 cells were
subjected to the 96-well IncuCyte scratch wound assay. The graph represents the
time kinetics of percent wound density, calculated by IncuCyte ZOOM software,
shown as mean ± SD, n=4; ****, P <.0001 (B) Control or SRSF9 knockdown
(siSRSF9) in HCT116 and SW480 cells were subjected to Transwell migration assay
through Matrigel®. The number of invaded cells per field was determined, (n=4); ****,
P <.0001. Representative microscopic images of the respective cells following
invasion through Matrigel® are shown. (C) Knockdown of SRSF9 was confirmed in
HCT116 and SW480 cells by Western Blot. (D) Western blot analysis of SRSF9, Ecadherin, N-cadherin, KSR1 and β actin expression following SRSF9 knockdown
using two siRNA oligonucleotides in HCT116 cells.

103

HCT116 Control vs KSR1 RNAi

180
160
140
120
100
80
60
40
20
0

Polysome mRNA
35.0%
Skipped

65.0%
included

-80 -60 -40 -20

0

20

40

60

180
160
140
120
100
80
60
40
20
0

Number of DSEs

Number of DSEs

A

Total mRNA
47.4%
included

52.6%
Skipped

-80 -60 -40 -20

80

0

20

40

60

80

ΔPSI (%)

ΔPSI (%)

180
160
140
120
100
80
60
40
20
0

Polysome mRNA
50.2%
Skipped

49.8%
included

-80 -60 -40 -20

0

20

ΔPSI (%)

40

60

80

180
160
140
120
100
80
60
40
20
0

Number of DSEs

Number of DSEs

HCT15 Control vs KSR1 RNAi
Total mRNA
50.7%
Skipped

49.3%
included

-80 -60 -40 -20

0

20

40

60

80

ΔPSI (%)
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SRSF9 associates with EPSTI1 RNA.
To determine whether SRSF9 is likely to directly regulate EPSTI1 splicing, we
searched for SRSF9 binding motifs in and around EPSTI1 exon 8 and exon 12 using
RBPmap, a computational tool for mapping RBP motif sequences derived from in vitro
and in vivo studies [199], a computational tool for mapping binding sites of RNA-binding
proteins, based on in vitro and in vivo experimentally derived binding motifs. Our
analysis identified two predicted SRSF9 binding motifs in intron 7 and seven motifs in
intron 12 (Figure 5.5A, Table 4). To experimentally determine whether SRSF9 interacts
with EPSTI1 mRNA, we carried out Ribonucleoprotein Immunoprecipitation (RIP) [119]
experiments, which investigate changes in the association of RNAs with an RBP by
immunoprecipitation analysis of native ribonucleoprotein (RNP) complexes. RIP analysis
detected EPSTI1 mRNA in immunoprecipitates of SRSF9 in both HCT116 and SW480
cells, which was abolished in cells with SRSF9 knockdown (Figure 5.5B). Upon
knockdown of SRSF9 in HCT116 and SW480 cells, we observed a decrease in EPSTI1
protein levels (Figure 5.5C). These data suggest that SRSF9 associates with EPSTI1
mRNA and may play a role in orchestrating splicing of EPSTI1 and regulating its protein
levels.

Inclusion of exon 8 of EPSTI1 mRNA is optimal to CRC motility.
Three spliced isoforms of EPSTI1 are annotated in reference databases, a fulllength transcript, a transcript skipping exons 8 and 12 and a transcript skipping exons
12. In the absence of exon 12, exon 11 splices to exon 13, but the reading frame of exon
13 is changed, so the amino acids normally encoded by exon 13 are missing (Figure
5.6A). We cloned all four EPSTI1 isoforms, along with an isoform lacking exon 8 only,
using site-directed mutagenesis (Figure 5.6B) and expressed them in KSR1 KO
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Figure 5.5 SRSF9 interacts with EPSTI1 RNA and SRSF9 inhibition suppresses
EPSTI1 expression
(A) Predicted SRSF9 binding motif in flanking introns of EPSTI1 between exon 7 and
exon 13 visualized using UCSC genome browser. The conserved binding motifs of
SRSF9 (akgavmr, kgrwgsm) were calculated by RBPmap using high stringency and
conservation filter. One colorized line represents one RBP binding motif. Longer line
means higher reliability. See Table 4. (B) Abundance of EPSTI1 and GAPDH mRNAs
in RIP experiments using anti-SRSF9 (SRFS9IgG) or control (RbIgG) IgG in SRSF9targeting (siSRSF9) or control (siControl) siRNA treated HCT116 and SW480 cells.
Levels are normalized to HPRT1 mRNA and plotted as fold-enrichment of mRNA
relative to IgG controls (n=3, ****; P<.0001) (C) Western blot analysis of SRSF9 and
EPSTI1 in control (siControl) and SRSF9 knockdown (siSRSF9) HCT116 and
SW480 cells. Experiments in (B-C) are representative of at least two independent
experiments.
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HCT116 and SW480 cells. We examined the ability of each isoform to restore motility in
KSR1 KO HCT116 and SW480 cells. Measuring wound density over 72h, we found that
the EPSTI1∆12∆13 isoform restored migration comparable to those observed in control
HCT116 cells (Figure 5.6C). The EPSTI1∆8∆12∆13 isofrom was approximately less
than half as effective in promoting migration as EPSTI1∆8∆12∆13 in HCT116 cells, while
the EPSTI1∆8 construct has no ability to rescue motility. These data suggest exon 8
inclusion is required for the function of EPSTI1 in CRC EMT.

Discussion

Tumor cells modify the messages encoding key proteins, changing, or enhancing
protein function to make tumor cells more lethal. The discovery that KSR1 regulates
EPSTI1 to promote the EMT-like phenotype raises new questions regarding how the
translation of EPSTI1 is regulated. Post-transcriptional mechanisms and pre-mRNA
splicing contribute to the plasticity required for EMT and establishment of more
aggressive neoplasms [88]. SFs and AS are critical points in gene expression regulation
but their role in EMT is incompletely explored.
Using a computational tool for identifying binding proteins regulating preferential
mRNA translation by KSR1, we showed that binding sites for the pre-mRNA SF SRSF9
were enriched in KSR1-dependent and polysome-associated mRNAs. KSR1 disruption
inhibits SRSF9 expression and promotes ubiquitin-mediated protein degradation. SRSF9
knockdown inhibits invasion of CRC cells coincident with its ability to decrease Ncadherin expression and upregulate E-cadherin. We further validated that SRSF9
associates with EPSTI1 mRNA, one of the KSR1-dependent targets that was identified
as a critical for EMT-like phenotype in CRC cells and inclusion of exon 8 is required for
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Figure 5.6 EPSTI1 exon 8 inclusion increases HCT116 cell motility in the
absence of KSR1.
(A) Structure of EPSTI1 genomic region and spliced isoforms. Exons are depicted in
boxes and introns in black lines. (B) Protein expression of FLAG-tagged full-length,
Δ8Δ12Δ13, Δ12Δ13, and Δ8 spliced isoforms of EPSTI1 transfected in HEK-293T
cells measured by western blot using a FLAG antibody, and HDAC2 as loading
control. (C) Control, KSR1 KO, and KSR1 KO cells expressing Δ8Δ12Δ13, Δ12Δ13,
and Δ8 EPSTI1 HCT116 and SW480 cells were subjected to the 96-well IncuCyte
scratch wound assay. The graph represents the time kinetics of percent wound
density, calculated by IncuCyte ZOOM software, shown as mean ± SD, n=4; ns,
nonsignificant; *, P <.0001; ***, P <.0001; ****, P <.0001. The cloning of EPSTI1
isoforms in Figure 5.6A was completed with the help of Robert Svoboda.
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the function of EPSTI1 in CRC EMT-like phenotype. Our AS analysis from the polysome
profiling RNA seq data suggests that KSR1 regulates AS events, particularly exon
skipping. Our future directions are aimed toward determining if, and how, KSR1
regulates EPSTI1 alternative splicing and whether a specific spliced isoform of EPSTI1
is translated preferentially in CRC to promote the EMT-like phenotype. Collectively these
data suggest that SRSF9 may be a key component of the regulatory mechanism that
monitors and directs the CRC cell phenotype toward self-renewal, motility, and invasion.
Previous studies have reported SRSF9 is an oncogenic SF [194, 200].
Compared to normal tissue, SRSF9 is overexpressed in a wide range of tumors
including glioblastoma, colon adenocarcinoma, and squamous cell lung carcinoma.
Some reports suggested that SRSF9 promotes colony formation and growth [194], while
others have reported SRSF9 promotes migratory capacity without affecting cell
proliferation [171]. SRSF9 is reported to promote growth via increased -catenin protein
synthesis [194] and via regulation of the apoptotic machinery [191, 193].
Determining how SRSF9-dependent induction of AS affects EMT should yield
unique mechanisms underlying tumor cell metastatic behavior. SRSF9 recognizes its
splicing targets via one of its two RNA recognition motifs (RRMs) that provide the
binding specificity to its targets and promote exon inclusion or skipping by interacting
with the splicing machinery via its C-terminal arginine/serine-rich (RS) domain. Discrete
mutations in distinct patches opposite to the putative RNA binding surface disrupt RNA
binding to SR domains, including SRSF9 [194]. Mutations in the SWQDLKD motif
(SWQDLKD to SAAALKD) impair RNA binding [194, 200]. Future experiments will be
directed toward identifying how SRSF9 expression promotes EMT in CRC cells. It is
likely that mutations in either of the RRMs will show RNA binding and processing are key
to the ability of SRSF9 to regulate EMT since SRSF9 interacts with EPSTI1 mRNA and
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phenocopies EPSTI1 action. We have shown that inclusion of exon 8 is optimal for
EPSTI1 function in regulating motility and invasion; however, it is not known what form of
EPSTI1 is preferentially translated to prime invasive behavior.
AS of EPSTI1 may not affect the association of its mRNA onto polysomes and
SRSF9 could contribute to additional mechanisms that promote their translation, via mRNA
export [185, 201]. Determining the extent of SRSF9-dependent EPSTI1 splicing and if
SRSF9 preferentially directs the specific isoform of EPSTI1 mRNA onto polysomes will
require additional studies.
While the role of KSR1 in Ras-driven tumorigenesis has been well established,
the role of KSR1 in the regulation of AS modulating translation of a subset of mRNAs
essential for EMT is a novel finding. We demonstrate for the first time that KSR1dependent signaling induces post-transcriptional splicing of a key target necessary for
CRC cells to promote their migratory and invasive behavior. Upon disruption of SRSF9,
the tumor cells reverse the mesenchymal-like behavior to an epithelial-like phenotype
and EPSTI1 was identified as one of the targets orchestrating this behavior in CRC cells.
It is highly possible that SRSF9 may be targeting other EMT-related mRNAs that are
preferentially translated in oncogene-driven signaling. Investigating other mRNAs
effected by SRSF9 may reveal a previously underappreciated contribution of alternative
splicing to cell migration, invasion, and EMT. The discovery of previously unknown
mechanisms essential for EMT in cancer cells has the potential to reveal processes
necessary for metastasis that may also be vulnerable to therapeutic manipulation.
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6. Chapter 6: KSR1 disruption sensitizes to
oncogene targeted therapies in colon
cancer cells
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Introduction

Colorectal Cancer (CRC) is the third leading cause of cancer-related mortality
and morbidity in men and women [17]. Almost half of the patients undergoing primary
CRC resection develop metastases during their lifespan [19]. Despite the development
of treatment regimens, there is no effective therapy for patients with advanced CRC [19].
Signaling pathways that are active in CRC are strongly regulated within the tumor.
Activating Ras mutations, present in 30-50% of CRC, are known to be drivers of
tumorigenesis and metastases and determinants of response to therapeutic regimens
[20]. Anti-EGFR therapies have a favorable survival impact in patients with wild-type
Ras, but patients with mutated Ras do not benefit from anti-EGFR therapy [202, 203].
Other than recent advances in selective inhibitors targeting the G12C variant of Ras
mutations, direct inhibition of mutant Ras isoforms remains a pharmacological challenge
[23]. Therefore, identifying effectors that transmit signals emanating from oncogenic Ras
remains a valuable step in detecting and targeting the adaptive pathways that CRC cells
use to resist chemotherapy.
Oncogenic Ras activates RAF/MEK/ERK signaling to promote cancer cell
proliferation. Although potent inhibitors for MAPK pathway have been developed targeting
RAF, MEK, and ERK, the use of these inhibitors as a monotherapy has been inadequate
[204-206]. Clinical effectiveness of therapeutic strategies targeting RAF, MEK, and ERK is
often limited by the mechanisms of acquired resistance [204] [207, 208]. An alternative
strategy to directly target mutant Ras necessitates the identification of co-dependent
signaling pathways essential for tumor survival coincident with effective therapeutic
inhibition of Ras-effector signaling pathways. Approaches for reducing the effective dose
of a therapeutic have the potential to suppress the acquired drug resistance and expand
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the clinical utility of an inhibitor. Combination therapy approaches will be needed to
achieve a prolonged anti-tumor response that makes the cells vulnerable to mechanisms
of resistance.
The molecular scaffold Kinase Suppressor of Ras 1 (KSR1) interacts with RAF,
MEK, and ERK, the Ras-activated effectors of the prototypical mitogen-activated kinase
(MAPK) cascade [11]. Disruption of KSR1 decreases MAPK pathway signaling and
KSR1-dependent signaling is critical for the maintenance of the tumor phenotype in cells
expressing oncogenic Ras [16, 96, 209]. However, KSR1 is dispensable for normal
development as ksr1-/- mice develop normally, are fertile, and show no debilitating
characteristics [122, 173]. KSR1 plays a critical role in coordinating and optimizing ERK1/2
activation [11, 93]. These characteristics suggest that KSR1 may serve as a valuable
therapeutic target because its disruption would be debilitating to tumors while having
little or no toxicity to the patient. Since KSR1 is required for oncogenic transformation in
Ras-mutated cancers, we hypothesized that KSR1 disruption may sensitize CRC cells to
MEK and ERK inhibitors, which could be exploited for selective cancer therapeutics.

Results

KSR1 disruption suppresses anchorage-independent growth in HCT116 and
HCT15 cells.
We targeted KSR1 in HCT116, HCT15, and SW480 cells using CRISPR/Cas9.
We also expressed a KSR1 transgene in cells lacking KSR1 expression (Figure 6.1A).
KSR1 disruption inhibits cell anchorage-independent growth in vitro and tumor formation
in vivo [16]. Similarly, disruption of KSR1 by CRISPR/Cas9-mediated targeting
decreased HCT116, HCT15, and SW480 cell viability under anchorage-independent
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conditions simulated by poly-(HEMA) coating (Figure 6.1B). KSR1 transgene
expression restored cell viability in HCT116 and HCT15 cells lacking KSR1 (KSR1
CRISPR + KSR1). Like our previous findings, KSR1 disruption hampered the ability of
Ras transformed cells to form colonies on soft agar. The number of colonies formed in
HCT116, HCT15, and SW480 cells dramatically decreased by 75% in the absence of
KSR1. Forced expression of KSR1 restored colony formation to levels observed in
control cells (Figure 6.1C). As KSR1 contributes to the survival of colon cancer cell
lines, we hypothesized that KSR1 deficiency might sensitize CRC cells to clinically
approved inhibitors of the MAPK signaling pathway.

KSR1 depletion sensitizes CRC cells to ERK inhibitors.
To investigate the role KSR1 plays in Ras-dependent CRC survival, we
examined whether CRC cells with disrupted KSR1 show differential sensitivity to
RAF/MEK/ERK effector pathway inhibition. We first assessed effector pathway inhibition
under anchorage-independent conditions. Control and KSR1 knockout HCT116, HCT15,
and SW480 cells were seeded on poly-HEMA coated 96-well plates to simulate
anchorage-independent conditions then treated the cells with increasing doses of the
ERK inhibitor SCH772984. SCH772984 is a novel, selective, and ATP competitive
inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate RSK and
also inhibits phosphorylation of residues in the activation loop of ERK itself. We
assessed EC50 as the measure of drug potency, which measures the drug
concentration at half maximal inhibition. The EC50 of each inhibitor’s ability to suppress
viability was < 1.5 µM in control cells, in line with their reported action in other tumor
cells and their minimal effect in clinical trials [210-214]. In combination with KSR1
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Figure 6.1 Depletion of KSR1 suppresses clonogenicity and anchorageindependent cell viability in multiple CRC cells.
(A) KSR1 was deleted in the indicated CRC cell lines with a guide RNA targeting
KSR1. Disruption was confirmed by western blot. A non-targeting control for each
line is shown for comparison. KSR1 transgene was introduced in the cells lacking
KSR1 expression and expression of the transgene was confirmed via western blot.
(B) The cell viability of control, KSR1 KO HCT116, HCT15 and SW480 cells plated
on poly-(HEMA)-coated plates was measured at the indicated days with or without
KSR1 (KSR1 KO + KSR1) expression. The data are shown as relative luminescence
units mean ± SD, (n=6); ***, P <.001; ****, P <.0001. The data were analyzed for
statistical significance by one-way ANOVA followed by t-test. The data are illustrated
as the number of colonies present after two weeks, (n=6) mean ± SD. ****, P <.0001.
Data were analyzed for statistical significance one-way ANOVA followed by t-test.
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disruption, the ERK inhibitor strongly decreased the viability of CRC cells. The EC50
was approximately 0.2 µM in HCT116 and SW480 controls and 1.1 µM in HCT15. The
EC50 improved by 4-fold, 14-fold and 2-fold in KO HCT116, HCT15 and SW480 cells
respectively (Figure 6.2). These results demonstrate that KSR1 depletion increases the
responsiveness to an ERK inhibitor in a panel of CRC cell lines.

KSR1 depletion in non-transformed colon epithelial cells does not mimic the
sensitivity to ERK inhibition.
Since KSR1 depletion suppresses growth in CRC cells with mutant Ras and not
non-transformed colon cells [16], we hypothesized that KSR1 disruption will sensitize
CRC cell lines to ERK inhibition and will have no-additive effect on the non-transformed
colon epithelial cells (HCECs). In 2D monolayer culture, the HCECs show an
undifferentiated phenotype, but form crypt-like structures in 3D culture. They are
incapable of anchorage-independent growth or tumor formation in nude mice yet retain
the ability to self-organize and differentiate in Matrigel culture [110]. To determine if
KSR1 disruption, in combination with ERK inhibitors, has an additive-effect on the
viability of HCECs compared to the inhibitors alone, KSR1 was targeted by siRNA
(Figure 6.3A) and cells were treated with different doses of the ERK inhibitor (Figure
6.3B). Disruption of KSR1 did not increase the potency of the ERK inhibitor as
comparing to the control suggesting that the additive effect if inhibiting the function of
both ERK and KSR1 was limited to CRC cells and not their non-transformed
counterparts.
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Figure 6.2 KSR1 depletion sensitizes CRC cells to ERK inhibitor.
Control and KSR1 KO (A) HCT116, (B) HCT15, and (C) SW480 cells were treated with
the indicated doses of the ERK inhibitor, SCH772984 (ERKi) on poly-HEMA coated
plates to stimulate anchorage-independent conditions for 72 hours. Viability was
measured using CellTiter-Glo. Data are presented as Mean ± SD. Data were normalized
and the EC50 for each cell line was calculated using an algorithm for fitting a non-linear
curve with variable slope in GraphPad Prism. (Right) Box plots represent the LogEC50
values for each cell line (n=3, mean ± SD. *, P <.05; **, P <.01; ***, P <.001)
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KSR1 deletion sensitizes CRC cells to MEK and RAF inhibitors.
To confirm the lower EC50s seen with the ERK inhibitor in cells lacking KSR1
was due to the inhibition of the MAPK pathway and not due to off-target effects, a panel
of CRC cells was treated with increasing concentrations of pan-RAF inhibitor LY3009120
or the MEK1/2 inhibitor PD0325901 and anchorage-independent cell viability was
measured as described above. Similar to what we observed with ERK inhibitors, in
combination with KSR1 disruption, anchorage-independent proliferation was inhibited at
lower drug concentrations compared to the control cells, with a significant shift to the left
in each dose-response curve. The EC50 of the MEK inhibitor improved by 150-fold in
HCT116, approximately 30-fold in HCT15 and 3-fold in SW480 cells (Figure 6.4). The
EC50 of pan-RAF inhibitor LY3009120 improved 19-fold, 2-fold, and 6-fold in HCT116,
HCT15, and SW480 cells (Figure 6.5). These results suggest that KSR1 disruption
sensitizes CRC cells to inhibitors of RAF, MEK, and ERK in a panel of CRC cells.

KSR1 knockout cells are less sensitive to ERK inhibitor in 2D growth conditions.
Previous studies show that 3D cell culture mimics properties intrinsic to in vivo
conditions, while cells plated in monolayer do not retain the proper tissue architecture
and cell-cell contacts [215]. Other studies have observed differences in signaling
pathways in 2D vs 3D growth conditions [216]. To confirm these findings and extend
these studies to ERK and MEK inhibitors, we assessed the dose-dependent cell viability
of control and KSR1 knockout HCT116 cells to either ERK or MEK inhibitors under 2Dgrowth conditions. HCT116 cells showed responsiveness to both ERK and MEK
inhibitors under 2D conditions; however, under 2D culture conditions KSR1 knockout
cells showed < 1 log enhancement in ERK and MEK inhibitor efficacy and suppressed
overall growth. Notably, statistically significant sensitivity to ERK inhibitor conferred to

119

Figure 6.4 Disruption of KSR1 sensitizes CRC cells to MEK inhibitor.
Control and KSR1 KO (A) HCT116, (B) HCT15, and (C) SW480 cells were treated
with indicated doses of MEK inhibitor, PD0325901 (MEKi) for 72 hours. Anchorageindependent viability was measured using CellTiter-Glo. Data are presented as Mean
± SD. Data were normalized and the EC50 for each cell line was calculated using an
algorithm for fitting a non-linear curve with variable slope in GraphPad Prism. (Right)
Box plots represent the LogEC50 values for each cell line, (n=3, mean ± SD. **, P
<.01; ***, P <.001; ****, P <.0001).
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Figure 6.5 KSR1 inhibition sensitizes CRC cells to RAF inhibitor.
Control and KSR1 KO (A) HCT116, (B) HCT15, and (C) SW480 cells were treated
with indicated doses of RAF inhibitor, LY3009120 (RAFi) for 72 hours. Anchorageindependent viability was measured using CellTiter-Glo. Data are presented as Mean
± SD. Data were normalized and the EC50 for each cell line was calculated using an
algorithm for fitting a non-linear curve with variable slope in GraphPad Prism. (Right)
Box plots represent the LogEC50 values for each cell line, (n=3, mean ± SD. *, P
<.05; ***, P <.001; ****, P <.0001).
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Figure 6.6 Sensitivity of KSR1 knockout HCT116 cells to ERK and MEK
inhibitors in 2D-growth conditions.
Control and KSR1 KO HCT116 cells were treated with indicated doses of (A) ERK
and (B) MEK inhibitor for 72 hours. Viability was measured using CellTiter-Glo. Data
are presented as Mean ± SD. Data were normalized and the EC50 for each cell line
was calculated using an algorithm for fitting a non-linear curve with variable slope in
GraphPad Prism. (Right) Box plots represent the LogEC50 values for each cell line,
(n=3, mean ± SD. *, P <.05; ns, non-significant).
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tumor cells by KSR1 disruption were evident only under anchorage independent growth
conditions and not in 2D culture conditions. KSR1 disruption sensitized to ERK inhibitor
by 1.7-fold and the MEK inhibitor by 1.2-fold (Figure 6.6). These findings suggest that
care must be taken to choose the appropriate culture system to identify and test novel
approaches for targeting tumors with activated Ras and that anchorage-independent
three-dimensional growth screens should be used to supplement, if not supplant twodimensional screens [217, 218].

AMPK signaling may contribute to the enhanced sensitivity in the absence of
KSR1.
Human cancer cells resistant to mTOR inhibition have hyperactivated Ras-MAPK
signaling [219, 220]. Cancer cells treated with ERK inhibitors develop resistance viaERK independent mechanisms [221, 222]. We confirmed that the RAF, MEK, or ERK
inhibitors blocked the signaling downstream of their intended target by comparing the
phosphorylation of RSK in treated and untreated HCT116 cells (Figure 6.7A). However,
in the absence of KSR1, SW480 cells showed differences in the responsiveness to ERK
and MEK inhibitors in comparison to the control cells. KSR1 promotes tumor cell survival
either downstream of its role as a scaffold in RAF/MEK/ERK kinase cascade or
independent of its role as scaffold through positive regulation of AMPK [16, 100]. AMPK
mediates KSR1-dependent signaling crucial for CRC transformation [16]. We tested the
effect of KSR1 on AMPK activity in cells with and without KSR1 expression. Disruption of
KSR1 in HCT116 or HCT15 cells suppressed the activation of AMPK as monitored by
phosphorylation at Thr172 (Figure 6.7B). However, the suppression of AMPK
phosphorylation was not evident in SW480 cells with KSR1 depletion. This suggests a
hypothesis that KSR1 mediates resistance to inhibitors of these pathways in a manner
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independent of its role as a MAPK scaffold. Subsequent studies showed that in nonsmall cell lung cancer cell lines bearing activating Ras mutations, KSR1 knockout
markedly enhanced the EC50 for the clinically relevant MEK inhibitor, trametinib (Robert
Kortum, USU, unpublished results). Furthermore, KSR1 KO promoted synergy by the
combined treatment of trametinib and AMPK inhibitor dorsomorphin in NSCLC H460
cells. This synergy was lost by KSR1 disruption but KSR1 knockout was sufficient to
prevent trametinib resistance in Ras-mutated H460 cells (Robert Kortum, USU,
unpublished results). These data support a role of KSR1 as an essential component of
both MEK and AMPK activity and reveal the value of disrupting KSR1 and/or inhibiting
both of the KSR1-regulated effector pathways to suppress drug resistance. These data
suggest a mechanism whereby AMPK-signaling confers resistance following MAPK
pathway inhibition. In this model, the absence of KSR1 sensitizes tumor cells to AMPK
pathway inhibitors because KSR1-dependent AMPK signaling is impaired. The KSR1dependent mechanism mediating MAPK pathway inhibitor responsiveness can be tested
further by rescuing KSR1 function in CRISPR-targeted KSR1 cells with ectopic KSR1mutant constructs previously shown to lack the ability to interact with AMPK signaling
[92, 93, 100, 223].

KSR1 signaling regulates resistance to MEK inhibitor trametinib.
We tested the resistance to trametinib in control or KSR1 knockout HCT116 and
HCT15 cells and assessed the impact of KSR1 depletion using a multi-well drug
resistance assay [224, 225]. Low confluence cells were treated in a 96-well plate format
and scored weekly. Wells showing 50% confluence in the presence of trametinib were
scored as resistant. KSR1 KO prevented the outgrowth of resistant colonies. Trametinib
sensitivity was maintained for 5 weeks in KSR1 KO HCT116 cells, while untargeted
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control HCT116 cells showed complete resistance in 2.5 weeks. An intact KSR1
restored resistance to trametinib in KSR1 KO HCT116 cells to levels observed in control
HCT116 cells (Figure 6.8). These results suggest that maintenance of KSR1 signaling is
critical in mediating resistance to a clinically relevant MEK inhibitor for several weeks,

Discussion

Many inhibitors of signaling pathways, including the RAF/MEK/ERK kinase
cascade have shown limited efficacy due to either acquired resistance of the targeted
tumor cells or limited potency in clinical trials. This study aimed to characterize the
diverse processes exploited by CRC cells to promote tumor progression and survival
and identify signaling nodes common to distinct tumors that may be exploited for
therapy. Our data demonstrate that disruption of KSR1 markedly enhances the efficacy
of RAF, MEK, and ERK inhibitors in CRC cell lines expressing activated Ras. Our data
also suggest that KSR1 mediates resistance to MAPK inhibitors in a manner
independent of its role as a scaffold for RAF, MEK, and ERK in cancers expressing
oncogenic Ras. If correct, the characterization of mechanisms used by KSR1 to alter
sensitivity to MAPK pathway inhibitors and determination of the breadth of pathways
affected by KSR1 disruption should reveal new strategies for boosting the effectiveness
of clinically tested inhibitors. By identifying mechanisms that disrupt this regulation
critical to tumor growth and survival, the studies in this proposal will advance our
knowledge of CRC tumorigenesis. This observation raises the possibility that KSR1
disruption will have similar effects in other cancers driven by oncogenic Ras or cancers
that depend upon Ras-dependent MAPK signaling for viability and growth. If true,
pharmacological approaches for disrupting KSR1 may have clinical potential. Developing
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Figure 6.8 KSR1 depletion in CRC cells delays the development of resistance
to a clinically approved MEK inhibitor.
Control, KSR1 KO and KSR1 KO (A) HCT116 and (B) HCT15 cells expressing a
KSR1 transgene (+KSR1) were subjected to a multi-well drug resistance assay. 300
cells for each condition were plated in a 96-well plate and treated with EC85
Trametinib (MEKi) weekly. Wells were scored as resistant when >50% confluent.
Percent growth inhibition was plotted as Kaplan-Meier curve, P<.0001 for Control and
KSR1KO+KSR vs KO.
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a preclinical approach for disrupting KSR1 will serve as a proof-of-principle for potential
new therapies against Ras-dependent tumors.
.
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7. Chapter 7: Discussion and Conclusions
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Translational control of KSR1-dependent ERK signaling in Rasmutant CRC cell lines

This work expands upon the initial studies from our lab demonstrating that KSR1mediated regulation of mRNA translation directs the fate of transformed colon epithelial
cells in a manner that supports their survival. Disruption of KSR1 in CRC cells inhibits
cap-dependent and cap-independent translation through phosphorylation and inhibition
of Eukaryotic translation initiation factor 4EBP1 and coincident increase in the
expression of PDCD4 [98]. The current study showed the sensitivity of phosphorylated
4EBP1 and PDCD4 to ERK inhibition in human colon organoids with mutant KRas only
and also in the quadruple mutant organoids (KAPS), thus extending our findings beyond
cell lines and validating that the biological mechanisms we are pursuing are maintained
in both cell lines and preclinical models. The regulation of the essential components of
mRNA translation suggests that KSR1-dependent modifications alter the translational
landscape of CRC cells, and characterized effectors repurposed by this dysregulation
will reveal specific mechanisms critical to cancer cell survival.
The mRNAs preferentially loaded onto ribosomes, repurposed by KSR1-dependent
mechanisms, will reveal specific proteins critical to colon cancer cell survival. To identify the
identities of mRNA repurposed by this mechanism, we performed polysome profiling
analysis to delineate the translational program induced by KSR1 in Ras-mutant cells. There
are multiple strengths to our screen; first, gene expression analysis historically focused
on measuring mRNA levels. However, we know mRNA levels are an imperfect proxy for
protein production because mRNA translation is subject to extensive regulation. We
expanded our efforts to efficiently monitor gene expression and protein production by
measuring mRNAs recovered from translating ribosomes. Secondly, our detection of
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mesenchymal mRNAs and stem-cell related mRNA among the significantly regulated
transcripts enable us to predict that inhibiting KSR1 or KSR1-dependent targets offers
the dual advantage of impairing motility and invasion of cancer cells while hampering the
tumor-initiation capabilities in Ras-driven CRC cells. Our demonstration that EPSTI1 and
DLL1 are translationally regulated to control expression of proteins critical for the
regulation of cell adhesion during EMT and self-renewal respectively, allows the
identification of additional transcripts that contribute similarly to other pathways such as
apoptosis, the inflammatory response or adipogenesis identified from the GSEA. Lastly,
we focused this screen on two Ras-mutant CRC cell lines rather than just HCT116 cells
as was previously performed [97, 106]. Performing the screen in one cell line would bias
the identification of targets that are specific to that cell line, and potentially less to other
CRC cells.
The current approach is limited by a few confounding factors that could be
addressed in the future to fully realize the true potential of translational reprogramming
by KSR1 signaling. Although, polysome profiling can provide a useful estimate of protein
synthesis, this approach lacks the resolution and accuracy of techniques like ribosome
profiling to determine translational activity [226]. Cis- and trans-acting regulatory proteins
interact with 5′ and 3′ untranslated regions and coding regions of mRNA coordinate
translation [227]. Upstream open reading frames in the 5’UTR sequences result in
ribosome binding to the mRNA while preventing translation of the transcript [228]. Some
of the polysome-bound mRNAs are arrested and not translated following acute changes
in the environment such as induction of hypoxia [229]. To examine these differential
effects, ribosome profiling followed by deep sequencing of the ribosome protected
fragments can create precise ribosome footprints at the codon level [226].
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While transient KSR1 knockdown [98] and CRISPR/Cas9-mediated KSR1
knockout affected the phosphorylation of 4EBP1 and expression of Myc, stable
knockdown of KSR1 did not. Therefore, the subset of mRNAs identified in the polysome
profiling analysis were likely to be translationally regulated in an eIF4E-independent
manner and may underrepresent the number of the mRNAs affected by KSR1dependent signaling. Performing a similar experiment in the KSR1 knockout cells could
reveal additional transcripts that contribute similarly to EMT, self-renewal, and other
tumor cell properties.

EPSTI1 is necessary and sufficient for generation of an EMT-like
phenotype in the absence of KSR1-dependent signaling

Metastasis is the major cause of death in patients with CRC. Almost 20% of
patients harbor with metastases at the initial presentation. The most common sites for
metastasis are the lung, liver, and peritoneum. Most of the patients have unresectable
lesions, rendering the disease uncurable [18, 230, 231]. Activation of EMT plays an
important role in invasion and metastasis [26]. The complexity of mechanisms impacting
EMT in cancer highlights a challenge to its investigation and the need to characterize
new mechanisms driving EMT. Cadherin cell-cell adhesion receptors are the main
regulators contributing to this adhesive dysfunction in cancer [39, 40]. Loss of Ecadherin and aberrant expression of N-cadherin promotes tumor progression to
invasion, metastasis and EMT [41, 42]. Importantly, the post-transcriptional control of
EMT regulators at both the mRNA and protein levels is crucial in controlling EMT. The
molecular mechanisms that drive tumor cells to these phenotypes are incompletely
understood.
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Differential gene expression analysis of cell lines established from primary CRC and
corresponding peritoneal metastasis, identified EPSTI1 among the five genes
upregulated in peritoneal metastatic cell lines [230]. Additional studies have described a
link between EPSTI1 and tumor metastatic potential, supported by the evidence that
EPSTI1 is highly upregulated in invasive breast cancer tissues and suggested a role of
EPSTI1 in promoting metastasis, tumorsphere formation, and stemness [164-166].
EPSTI1 is upregulated in human breast tumor cells co-cultured in 3D with fibroblasts,
and is upregulated strongly in the epithelial fraction of invasive breast carcinomas
compared with normal breast [165, 232]. In addition, EPSTI1 induces invasion and
metastasis of non-invasive breast cancer cell lines in vitro and in vivo [166, 233]. In
breast cancer cells, KLF8 was found to directly upregulate the expression of EPSTI1 by
transcriptional activation of its gene promoter and EPSTI1 was shown to interact with
p97 Valosin-containing protein (VCP) to promote the degradation of IκBα and activation
of NFκB [165]. Induction of EPSTI1 was also shown to promote EMT characteristics by
inducing the mRNA expression of the transcriptional regulators, Slug and Twist mRNA,
and the subsequent expression of fibronectin and α2β1 integrins [166]. An emphasis on
defining the EMT based program solely on the basis of the mRNA expression of specific
molecular markers such as these provides an incomplete perspective on the enormous
complexity and plasticity involved in EMT [34]. Additional studies are required to
understand the contributions of EPSTI1 to motility, invasion, and EMT.
In this study, we demonstrate the KSR1- and ERK-dependent induction of EPSTI1
mRNA translation. We observed that, while the TE of EPSTI1 was markedly decreased
by KSR1 depletion, EPSTI1 total transcript levels were not altered. Although, EPSTI1
protein expression decreased with KSR1 disruption, KSR1 did not appear to affect
EPSTI1 protein stability. Further, EPSTI1 is both necessary and sufficient for
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coordinating the up-regulation of N-cadherin with the downregulation of E-cadherin to
stimulate cell motility and invasion in colon cancer cells. These data suggest that EMT is
not only mediated through transcription, but mRNA translation plays a previously
underappreciated role in driving cells in the interconversion between epithelial and
mesenchymal fates.
Previous studies show that EPSTI1 promotes breast tumor invasion and metastasis
only and EPSTI1 did not play a role in regulation of cell proliferation [165]. However, in
our study EPSTI1 was found to promote growth in CRC cell lines under 2D and 3D
culture conditions. These results suggest that the function of EPSTI1 may differ between
cancer cell models. Therefore, more investigations are warranted to investigate the
mechanistic action of EPSTI1, such as posttranscriptional modifications and interacting
partners.
EPSTI1 contains coiled-coil regions in positions 74–101, 128–188, and 226-265
[164]. Inspection of the NCBI reference sequence for EPSTI1 reveals a predicted 95
amino acid BAR domain at position 95-189, encapsulating the central and largest coiled
coil. Though some BAR domains form heterodimers and facilitate protein-protein
interactions, BAR domains typically form homodimers, and are best understood for their
ability to promote membrane curvature and macromolecular assembly [234-236]. One or
more coiled-coil domains may be critical for EPSTI1 effects on EMT and deletion of any
of the three helices could disrupt EPSTI1 function. EPSTI1 was also shown to interact
with VCP to induce degradation of IkBα and activate NFkB. p97 is a hexameric AAA
ATPase linked to protein degradation that uses ATP hydrolysis to remodel or unfold
client proteins. Given the role of p97 in protein degradation and our observation that
EPSTI1 knockdown suppresses the expression of EMT-TFs Zeb-1 and Slug, but not
their mRNA expressions, it is possible the interaction of EPSTI1 with p97 is critical to the
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stability of these EMT-TFs and the inhibition of E-cadherin. Determining if this proteinprotein interaction is necessary for EMT will require additional studies. More
investigations are worth pursuing to understand the mechanistic role of EPSTI1 signaling
contributing to EMT and potentially as a therapeutic target.
KSR1 or EPSTI1 disruption inhibits cell transformation in vitro and in primary tumor
growth in vivo [16, 165], but its potential role in EMT and metastasis has not been
tested. Coupled to our observations implicating both KSR1 and EPSTI1 to EMT in vitro,
these observations suggest a rationale for testing their ability to affect EMT in disease
models. This work is limited by the lack of an in vivo model to support our findings that
EPSTI1 plays an important role in promoting the invasion and motility of cancer cells,
future work should be applied to evaluate the in vivo utility of targeting EPSTI1. Given
the association of EPSTI1 with promotion of the metastatic potential in tumor cells,
disruption of this regulation will prove efficacious for developing therapeutic strategies.

SRSF9 may contribute to splicing of mRNAs essential for the EMTlike phenotype

The discovery that KSR1 regulates EPSTI1 to promote the EMT-like phenotype
raises new questions regarding how the translation of EPSTI1 is regulated. RNA binding
proteins affect discrete cell behaviors, including motility and invasion, by selectively
regulating pre-mRNA splicing, mRNA stability, and localization. The following preliminary
observations led to the hypothesis that intermediaries modulating post-transcriptional
regulation of mRNAs contribute to plasticity required for EMT in CRC cells. We identified
eight RBPs that were predicted to interact with KSR1-dependent mRNAs and the
binding sites for SRSF9 were disproportionately depleted by KSR1 knockdown among
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others. KSR1 appears to inhibit SRSF9 protein degradation and SRSF9 knockdown
inhibits invasion of CRC cells in association with a decrease in N-cadherin expression.
SRSF9 was found to associates with EPSTI1 mRNA and inclusion of exon 8 is critical for
the ability of EPSTI1 to promote CRC cell motility. These data suggest that SRSF9 may
alter the splicing of EPSTI1 to enhance its translation as a means of promoting EMT
(Figure 7.1).
The ability of SRSF9 to phenocopy the effects of KSR1 and interact with EPSTI1
mRNA identifies it as an effector of KSR1-dependent signaling. Thus, it is likely that
SRSF9 is a key component of the regulatory mechanism that monitors and directs the
CRC cell phenotype toward motility and invasion. However, it is not known where
SRSF9 binds to EPSTI1 mRNA. There are no publicly available datasets with SRSF9
binding in CRC cells, limiting our ability to directly link SRSF9 binding and its effect on
EPSTI1 splicing. To overcome these limitations, we can perform crosslinking
immunoprecipitation (CLIP)-PCR to identify the position of direct protein-RNA interaction
using crosslinking immunoprecipitation [237]. This will allow us to determine if SRSF9 is
a predominant interactor with mRNAs whose translation is regulated by KSR1, as
predicted by PRADA.
Our preliminary data suggest the hypothesis that SRSF9 promotes the inclusion
of exon 8 in EPSTI1. Further studies need to be performed to evaluate the contribution
of EPSTI1 isoforms to the cadherin switch, motility, and invasion. Inspection of the NCBI
reference sequence for EPSTI1 reveals a predicted 95 amino acid BAR domain at
position 95-189, encapsulating the central and largest coiled coil. Though some BAR
domains form heterodimers, BAR domains typically form homodimers, and are best
understood for their ability to promote membrane curvature and macromolecular
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Figure 7.1 Summary schematic of the proposed KSR1-SRSF9-EPSTI1 signaling
axis in CRC cells.
These data shown in this dissertation suggest a novel pathway whereby KSR1dependent ERK signaling regulates SRSF9 expression and SRSF9, in turn, regulates
EPSTI1 to promote cadherin switching, motility, and invasion. Figure was created
with BioRender.com
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assembly [238]. Exon 8, which encodes sequences immediately distal to the BAR
domain may affect homotypic and/or heterotypic interactions of EPSTI1 that are critical
to CRC EMT.
We hypothesize that, like EPSTI1, SRSF9 modulates the post-transcriptional
mechanisms mRNAs to affect their function. By comparing the effect of SRSF9
disruption on translation of mRNAs highlighted by polysome profiling, we can identify
new translationally regulated transcripts affected by the SRSF9 splicing program. These
results should shed light on unappreciated roles in EMT for SRSF9 and for the mRNAs it
regulates in EMT.

KSR1 disruption sensitizes CRC cells to MAPK pathway inhibitors

Oncogenic Ras activates MAPK signaling to promote cancer cell proliferation.
KSR1 plays a critical role in coordinating and optimizing ERK1/2 activation [11, 93].
Although, potent inhibitors targeting the MAPK pathway effectors have been developed
targeting RAF, MEK, and ERK have been developed, the use of these inhibitors in
monotherapy has been inadequate [204-206, 212]. Reports show the role of sustained
MAPK signaling in mediating acquired resistance to MAPK pathway inhibition in Rasmutated cancers [207, 208]. We observed that cells lacking KSR1 showed increased
responsiveness to RAF, MEK, or ERK inhibitors in a panel of CRC cell lines. We further
demonstrated that KSR1 is required for trametinib resistance. KSR1 promotes tumor cell
survival either downstream of its role as a scaffold in the RAF/MEK/ERK kinase cascade or
independent of its role as scaffold through positive regulation of AMPK. As seen in CRC
cells, in a non-small cell lung cancer cell line, H460, KSR1 depletion enhanced the
sensitivity to the MEK inhibitor trametinib. Synergy was obtained by combined treatment with
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MEK inhibitor and AMPK inhibitor which was lost by KSR1 disruption (Robert Kortum, USU,
unpublished results). Similar to KSR1 depletion, the addition of the AMPK inhibitor was
sufficient to overcome resistance to trametinib. These data suggest that KSR1 is an
essential contributor to AMPK activity in cancer cells and emphasize the value of disrupting
KSR1 or KSR1-regulated pathways to overcome drug resistance (Figure 7.2). These
works create a foundation on which to characterize of the diverse processes exploited by
CRC cells to promote tumor progression and survival and identify signaling nodes
common to distinct tumors that may be exploited for therapy. By identifying mechanisms
that disrupt this regulation critical to tumor growth and survival, the studies in this
proposal will advance our knowledge of CRC tumorigenesis.

Conclusions

In summary, we have identified the KSR1-SRSF9-EPSTI1 signaling pathway as
a novel signaling axis downstream of oncogenic Ras that promotes the invasion and
metastasis of CRC cells. This work has opened a new avenue for colon cancer
mechanistic studies and provided a new avenue of exploration for the development of
novel therapeutic strategies against CRC. We demonstrate for the first time that KSR1
alters the translational landscape in colon cancer cells and coordinates the production of
protein components essential to EMT and possibly resistance to therapy. This work will
provide strategies for expanding the therapeutic window of existing MAPK pathway
inhibitors. These studies highlight previously unappreciated roles in EMT for the RBP
SRSF9 and for EPSTI1. These experiments will provide a rationale essential for future
experiments that 1) discover what splicing events control the preferential translation of
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Figure 7.2 Summary schematic of the working hypothesis that KSR1 disruption
sensitizes CRC cells to MAPK pathway inhibitors.
A. KSR1-association with AMPK renders the CRC cells resistant to RAF
(LY3009120), MEK (PD325910, trametinib), or ERK (SCH772984) inhibitors. B.
Disruption of KSR1-associated AMPK will sensitize CRC cells to MAPK pathway
inhibitors. Figure was created with BioRender.com
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mRNAs onto polysomes and how their translation is coordinated to promote tumor cell
properties, 2) identify the other key components of the splicing machinery that control
preferential translation, and 3) direct focus on the critical pathways in which
translationally regulated EMT occurs.
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Table 3 Genes translationally altered by KSR1

Sl.No.

Gene Symbol

Log2 FC (TE)

p-value

1

RN7SKP173

-2.12

0.010526

2
3

AC016074.2
FKBP2

-1.93
-1.63

0.022299
0.000661

4
5

RP11-89K21.1
GLT8D2

-1.61
-1.53

0.013317
0.025778

6
7
8
9

AC034139.1
EPSTI1
RUNX3
RP11-462G12.1

-1.41
-1.40
-1.39
-1.38

0.041679
0.003656
0.024100
0.008471

10
11

KIAA1377
AC074289.1

-1.26
-1.26

0.025489
0.009760

12
13

MURC
RP11-119F7.5

-1.25
-1.24

0.006237
0.014357

14
15

WNT9A
RP11-417L19.4

-1.23
-1.21

0.025868
0.018054

16
17
18
19
20
21
22
23
24
25

GRM2
DLL1
CTD-2619J13.17
RNF112
HOXA10-AS
HOXC8
AC245140.3
FRMPD1
LRRN4
COL13A1

-1.19
-1.18
-1.12
-1.03
-1.02
-1.02
-1.01
-0.99
-0.95
-0.93

0.020653
0.010732
0.004376
0.011236
0.006914
0.023323
0.031525
0.020411
0.011565
0.005897

26
27

CTC-453G23.8
PTPRN2

-0.93
-0.92

0.004409
0.002917

28
29
30
31
32
33
34

BEND3P3
RP11-448G15.3
MT-TF
MRC2
P2RY1
MGAT2
LHX9

-0.91
-0.91
-0.90
-0.88
-0.87
-0.87
-0.86

0.010644
0.022294
0.022067
0.025039
0.019079
0.022811
0.012179
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35
36
37
38
39
40
41
42
43
44
45
46
47
48

MTMR9
USP2
IFIT3
RP11-218C14.8
ABCG2
EGR2
RP11-713C19.2
ZFP2
RASD1
RP11-757G1.6
KIAA0825
SOBP
CEP19
AQP1

-0.82
-0.81
-0.81
-0.79
-0.76
-0.76
-0.76
-0.75
-0.73
-0.70
-0.70
-0.69
-0.67
-0.67

0.030426
0.011305
0.021296
0.005042
0.009184
0.015341
0.033777
0.008896
0.024515
0.031518
0.014460
0.035367
0.013100
0.013263

49
50
51
52
53
54
55

TUBBP1
SEPTIN3
RP5-968P14.2
RP5-1139B12.3
HAL
VANGL2
FEZF1

-0.64
-0.62
-0.58
-0.57
-0.56
-0.55
-0.54

0.011810
0.038409
0.041242
0.018554
0.038409
0.026444
0.024427

56
57
58
59
60
61
62
63
64
65

AC009802.1
GALNT12
C3orf80
AUH
SLC11A1
RBM8B
MEF2BNB
APOBEC3H
BBC3
HIST1H2AC

-0.53
-0.53
-0.52
0.51
0.51
0.54
0.54
0.54
0.56
0.59

0.003870
0.027702
0.024221
0.049181
0.033908
0.041679
0.042614
0.027176
0.006004
0.024407

66
67
68
69
70
71
72
73

MRPS6
ARHGAP30
ACTRT3
VAMP5
RP11-432J22.2
EFCAB6
SUMO2P17
PRAC2

0.60
0.62
0.67
0.69
0.69
0.73
0.74
0.76

0.022841
0.032923
0.008309
0.023729
0.023571
0.005135
0.003038
0.025470
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74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97

SH2D6
AC073072.7
AC005932.1
RP11-54O7.18
CTC-490E21.10
AC005281.1
RP11-355B11.2
NFATC2
AC008155.1
HSD52
RP11-486I11.2
RP11-6B6.3
ZNF233
AP002813.1
EIF4A1P7
RP11-503N18.1
COX7C
CTD-2342J14.6
TCP10L
RP11-353N14.4
RP1-140A9.1
COX7CP1
RP11-663P9.2
RP11-85A1.3

0.77
0.80
0.81
0.82
0.84
0.86
0.90
0.93
0.94
1.00
1.02
1.05
1.05
1.06
1.07
1.09
1.09
1.10
1.10
1.23
1.28
1.32
1.33
1.37

0.033212
0.021478
0.031525
0.015558
0.022299
0.026496
0.005146
0.022930
0.019878
0.006602
0.008414
0.002162
0.018509
0.008471
0.003762
0.020907
0.001558
0.002788
0.007539
0.003870
0.015622
0.001676
0.004750
0.005673
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SLC51B

1.46

0.023832
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Table 4 RBP maps results for SRSF9 of EPSTI1 exons 7-9 and exon 11-13

Predictions for sequence: chr13:42886390-42895109:Calculation parameters:
Genome: Human (hg38)
Selected motifs: SRSF9(Hs/Mm):akgavmr, SRSF9(Hs/Mm):kgrwgsm
Stringency level: High
Conservation filter: On
Protein: SRSF9(Hs/Mm)
Sequence Position Genomic Coordinate
669
chr13:42894441
1674
chr13:42893436
3525
chr13:42891585
3535
chr13:42891575
5208
chr13:42889902
5633
chr13:42889477
5637
chr13:42889473

Motif
akgavmr
akgavmr
akgavmr
akgavmr
kgrwgsm
kgrwgsm
kgrwgsm

K-mer
acgagca
aagagaa
aggaaaa
aggagau
ggaagga
aggagga
ggaaggc

Z-score
2.323
2.292
2.938
2.8
2.634
2.704
2.831

P-value
1.01E-02
1.10E-02
1.65E-03
2.56E-03
4.22E-03
3.43E-03
2.32E-03

Z-score
2.015
2.708

P-value
2.20E-02
3.38E-03

Predictions for sequence: chr13:42917543-42926430:Calculation parameters:
Genome: Human (hg38)
Selected motifs: SRSF9(Hs/Mm):akgavmr, SRSF9(Hs/Mm):kgrwgsm
Stringency level: High
Conservation filter: On
Protein: SRSF9(Hs/Mm)
Sequence Position Genomic Coordinate Motif
2360
chr13:42924071
akgavmr
6153
chr13:42920278
akgavmr

K-mer
aagaaca
aggaaca
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Table 5 List of cell lines.

Cell lines

Source or
reference

Identifiers

Additional
Information

HCT116 (ATCC,
Cat# CCL-247,
RRID:
CVCL_0291)
HCT15 (ATCC,
Cat# CCL-225,
RRID:
CVCL_0292)
SW480 (ATCC,
Cat# CCL-228,
RRID:
CVCL_0546)

Colorectal
carcinoma, epithelial

ATCC

Colorectal
carcinoma, epithelial

ATCC

Colorectal
adenocarcinoma,
epithelial

ATCC

Immortalized colon
epithelial

Obtained from Dr.
Jerry Shay, UT
Southwestern

HCEC

Kidney; epithelial
fibroblast (fetus)

ATCC

HEK-293T (ATCC
Cat# CRL-3216,
RRID:
CVCL_0063)

Kidney; epithelial
fibroblast (fetus)

Obtained from Rob
Kortum, Uniformed
Services University

Phoenix-GP

Available at
ATCC (Cat#
CRL-321)
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Table 6 List of transfected constructs.

Constructs

Source or reference

Identifiers

Additional Information

siRNA to nontargeting control

Dharmacon

Cat# D-001810-01-20

UGGUUUACAUGUCGACUAA

siRNA to EPSTI1

Dharmacon

Cat# 015094-09-0020

GAACAGAGCUAAACCGGUU

siRNA to EPSTI1

Dharmacon

Cat# 015094-12-0020

UCUGGAGGCUGUUGGAAUA

siRNA to SRSF9

Dharmacon

Cat# 015094-09-0020

GAGUGGGAUGGUCGAGUA

siRNA to SRSF9

Dharmacon

Cat# 015094-12-0020

UGAAAGGAUCACAUGCGAGA

siRNA to DLL1

Dharmacon

Cat # 009719-00-0005

siRNA to ERK1

Dharmacon

Cat# J-003592-100020

AGACUGACCUGUACAAGUU

siRNA to ERK2

Dharmacon

Cat# J-003555-110020

UCGAGUAGCUAUCAAGAAA

siRNA to RASD1

Dharmacon

Cat # 009719-00-0005
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Con shRNA#1

Fisher, et al., 2015

pLKO.1 MC1 puro

CAACAAGATGAAGAGCACCAA

KSR1 shRNA#1

Fisher, et al., 2015

pLKO.1 KSR.1 puro

GTGCCAGAAGAGCATGATTTT

KSR1 shRNA#2

Fisher, et al., 2015

pLKO.1 KSR.2 puro

GCTGTTCAAGAAAGAGGTGAT

CON sgRNA#1

This paper

pCAG-SpCas9-GFPU6-gNC1

GTATTACTGATATTGGTGGG

KSR1 sgRNA#1

This paper

pCAG-SpCas9-GFPU6-gCR1.1

TTGGATGCGCGGCGGGAAAG

KSR1 sgRNA#2

This paper

pCAG-SpCas9-GFPU6-gCR1.2

CTGACACGGAGATGGAGCGT

MSCV-KSR1
(plasmid)

Kortum, et.al, 2006

MSCV-KSR1-IRESGFP

MSCV-KSR-AAAP
(plasmid)

Kortum, et.al, 2006

MSCV-KSR1-AAAPIRES-GFP

FLAG-EPSTI1
(plasmid)

This paper

MSCV-FLAG-EPSTI1IRES-GFP

N-cad OE (plasmid)

Gift from Dr. Keith
Johnson, UNMC

N-cadherin-mGFP

FLAG-EPSTI1-tv2
(plasmid)

This paper

MSCV-FLAG-EPSTI1
∆8∆12∆13-IRES-GFP

FLAG-EPSTI1-tv3
(plasmid)

This paper

MSCV-FLAG-EPSTI1
∆12∆13-IRES-GFP
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FLAG-EPSTI1-tv X1
(plasmid)

This paper

MSCV-FLAG-EPSTI1
∆8-IRES-GFP
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Table 7 List of PCR primer sequences.

PCR
primers

Source
or
referenc
e

Identifiers

Additional Information

Forward primer 5’-GTGAATTACTGGAACTGAAACGG-3’
EPSTI1

IDT

Cat#
Hs.PT.58.5047167
8

Reverse primer 5’ TCCAACAGCCTCCAGATTG 3’ Tm 55ºC, Exon Location 10-11

Forward primer 5’-GTTTGCCAGTGTGACTCCA-3’
Ncadherin

IDT

Cat#
Hs.PT.58.2602444
3

Reverse primer 5’-CATACCACAAACATCAGCACAAG-3’
Tm 55ºC, Exon Location 13-14
Forward Primer: 5’ GTATTCATTATAGTCAAGGGCATATCC 3’

HPRT1

IDT

Cat#
Hs.PT.58v.456215
72

Reverse Primer: 5’AGATGGTCAAGGTCGCAAG 3’
Tm 60ºC, Exon Location 8-9

Zeb1

IDT

Forward primer 5’-GAGGAGCAGTGAAAGAGAAGG-3’
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Cat#
Hs.PT.58.3917857
4

Reverse primer 5’-TACTGTACATCCTGCTTCATCTG-3’
Tm 60ºC, Exon Location 3-5
Forward primer 5’-AGGACACATTAGAACTCACACG-3’

Slug

IDT

Cat#
Hs.PT.58.5047167
8

Reverse primer 5’-CAGATGAGCCCTCAGATTTGAC-3’
Tm 55ºC, Exon Location 2-3
Forward primer 5’-GTCGAGTATCTCAGAAAAGAAGACA-3’

SRSF9

IDT

Cat#
Hs.PT.58.5047167
8

Reverse primer 5’ CTCGGATGTAGGAAGTTTCACC 3’ Tm 58ºC, Exon Location 3-4

Forward primer 5’-GGCTCCTGGCAAAAGGTCA-3’
Myc

IDT

Reverse primer 5’-CTGCGTAGTTGTGCTGATGT-3’
Tm 58ºC, Exon Location 3
Forward primer 5’-GAGACTTCTGCTCTGAGTTCC-3’

TIMELES
S

IDT

Reverse primer 5’-CCAAGGCCCACATATAATAGGT-3’
Tm 62ºC, Exon Location 10-11

152

Forward primer 5’-CTCAGATCATTGTCACAGTCGT-3’
ABCG2

IDT

Reverse primer 5’-GTCGTCAGGAAGAAGAGAACC -3’
Tm 58ºC, Exon Location 10-11
Forward primer 5’-CCTCTCTGTAGCCCTTGGA-3’

AQP1

IDT

Reverse primer 5’-CCCACCCAGAAAATCCAGT-3’
Tm 61ºC, Exon Location 5-7
Forward primer 5’-GTGGGGAGAAAGTGTGCAA-3’

DLL1

IDT

Reverse primer 5’-GTCACAAATCCATGCTGCTC-3’
Tm 61ºC, Exon Location 4-5
Forward primer 5’-TCGAGTGCCAGTTCCAGT-3’

WNT9A

IDT

Reverse primer 5’-GCATAGAGGAAGGCAGTCTC-3’
Tm 58ºC, Exon Location 2-3
Forward primer 5’-GTAAATCCTCCGCCAACACTA-3’

HOXC8

IDT
Reverse primer 5’-AAGGTCTGATACCGGCTGTA-3’

153

Tm ºC 61, Exon Location 1-2
Forward primer 5’-GAACCTCGATCATCTTCCTGA-3’
USP2

IDT

Reverse primer 5’-GTAACCACAATCTGTACACGTCA-3’
Tm 58ºC, Exon Location 7-9
Forward primer 5’-GGTGAAGGTCGGAGTCAACGG-3’

GAPDH

IDT

Reverse primer 5’-GAGGTCAATGAAGGGGTCATTG-3’
Tm 58ºC, Exon Location 2-3
Forward primer 5’-CTGAGCCCGTGGAAGA-3’

EPSTI1
(FOR
RIP)

IDT

Reverse primer 5’-TCTCCGGTTTATATTTGGTGCT-3’
Tm 58ºC, Exon Location 1-2

EPSTI15P

IDT

5’TGTGAATTCGCCACCATGGACTACAAAGACGATGACGACAAGAACACCCGCAA
TAGAGTG

EPSTI13P

IDT

5’TCGCGGCCGCGTCGACTTAGAAAAATAATGTAGCATTTC

EPSTI
TV2/3-3P

IDT

5’GAAGTCGACTCATATACCCCAGCTGTTACCGCTATTCATATTC

EPSTI
TV2/3-3P

IDT

5’GAAGTCGACTCATATACCCCAGCTGTTACCGCTATTCATATTC
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Table 8 List of antibodies

Antibodies

Source or reference

Identifiers

Additional Information

anti-KSR1, Rabbit
polyclonal

Abcam

Cat# ab68483

WB (1:1000)

anti-EPSTI1, Rabbit
polyclonal

Proteintech

Cat# 11627-1-AP,
RRID: AB_2877786

WB (1:1000)

Gift from Dr. Keith
Johnson, UNMC

Cat# 13A9

WB (1:20)

Cell Signaling

Cat# 13116, RRID:
AB_2687616

WB (1:1000)

Gift from Dr. Keith
Johnson, UNMC

Cat# 4A2

WB (1:10) IF (1:1)

Cell Signaling

Cat# 3195, RRID:
AB_2291471

WB (1:1000)

anti-Slug, Rabbit
monoclonal

Cell Signaling Technology

Cat# 9585,
RRID:AB_2239535

WB (1:1000)

anti-Lamin B2, Rabbit
monoclonal

Abclonal

Cat# A6483, RRID:
AB_2767083

WB (1:2000)

anti-β actin, Mouse
monoclonal

Santa Cruz

Cat# 47778,
RRID:AB_2714189

WB (1:2000)

anti-N-cadherin

anti-E-cadherin

155
anti-phospho RSK
S380, Rabbit
polyclonal

Cell Signaling Technology

Cat# 9341, RRID:
AB_330753

WB (1:500)

anti-Total RSK,
Rabbit monoclonal

Cell Signaling Technology

Cat# 9355, RRID:
AB_659900

WB (1:1000)

anti-phospho p70S6K
T389, Rabbit
polyclonal

Cell Signaling Technology

Cat# 9206 RRID:
AB_2285392

WB (1:500)

Anti-total p70S6K,
Rabbit polyclonal

Cell Signaling Technology

Cat# 9202, RRID:
AB_331676

WB (1:1000)

anti-SNAIL, Rabbit
monoclonal

Cell Signaling Technology

Cat# 3879, RRID:
AB_2255011

WB (1:1000)

anti-Vimentin, Rabbit
monoclonal

Cell Signaling Technology

Cat# 5741,
RRID:AB_10695459

WB (1:1000)

anti-RASD1, Rabbit
polyclonal

Abcam

Cat# ab251924

WB (1:1000)

anti-Myc, Rabbit
monoclonal

Cell Signaling Technology

Cat# 5605

WB (1:500)

anti-PDCD4, Rabbit
monoclonal

Cell Signaling Technology

Cat# 9535

WB (1:1000)

anti-phospho 4EBP1
T70, Rabbit polyclonal

Cell Signaling Technology

Cat# 9455

WB (1:500)

156

anti-phospho 4EBP1
S 65, Rabbit
polyclonal

Cell Signaling Technology

Cat# 9451

WB (1:500)

anti-4EBP1, Rabbit

Cell Signaling Technology

Cat# 9644

WB (1:1000)

anti-phospho ERK1/2,
Rabbit polyclonal

Cell Signaling Technology

Cat# 9101

WB (1:500)

anti- ERK1/2, Rabbit
polyclonal

Cell Signaling Technology

Cat# 9102

WB (1:1000)

anti-PARP, Rabbit
polyclonal

Cell Signaling Technology

Cat# 9542

WB (1:1000)

anti-DLL1, Rabbit
polyclonal

Abcam

Cat# ab10554

WB (1:1000)

anti-SRSF9, Rabbit
polyclonal

MBL BIO

Cat# RN081PW

WB (1:1000)

anti-phospho-AMPKα,
Rabbit monoclonal

Cell Signaling Technology

Cat# 2535

WB (1:500)

anti-AMPKα, Rabbit
polyclonal

Cell Signaling Technology

Cat# 2532

WB (1:1000)

anti-Tubulin, Mouse
monoclonal

Santa Cruz

Cat# B-5-1-2

WB (1:2000)
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